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A B S T R A C T
Background
Pancreatic pseudocysts are walled-oG peripancreatic fluid collections. There is considerable uncertainty about how pancreatic pseudo-
cysts should be treated.
Objectives
To assess the benefits and harms of different management strategies for pancreatic pseudocysts.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library 2015, Issue 9, and MEDLINE, EMBASE,
Science Citation Index Expanded, and trials registers until September 2015. We also searched the references of included trials and con-
tacted trial authors.
Selection criteria
We only considered randomised controlled trials (RCTs) of people with pancreatic pseudocysts, regardless of size, presence of symptoms,
or aetiology. We placed no restrictions on blinding, language, or publication status of the trials.
Data collection and analysis
Two review authors independently identified trials and extracted data. We calculated the odds ratio (OR) and mean difference (MD) with
95% confidence intervals (CI) with RevMan 5, based on an available-case analysis for direct comparisons, using fixed-effect and random-ef-
fect models. We also conducted indirect comparisons (rather than network meta-analysis), since there were no outcomes for which direct
and indirect evidence were available.
Main results
We included four RCTs, with 177 participants, in this review. After one participant was excluded, 176 participants were randomised to en-
doscopic ultrasound (EUS)-guided drainage (88 participants), endoscopic drainage (44 participants), EUS-guided drainage with nasocystic
drainage (24 participants), and open surgical drainage (20 participants). The comparisons included endoscopic drainage versus EUS-guid-
ed drainage (two trials), EUS-guided drainage with nasocystic drainage versus EUS-guided drainage alone (one trial), and open surgical
drainage versus EUS-guided drainage (one trial). The participants were mostly symptomatic, with pancreatic pseudocysts resulting from
acute and chronic pancreatitis of varied aetiology. The mean size of the pseudocysts ranged between 70 mm and 155 mm across studies.
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Although the trials appeared to include similar types of participants for all comparisons, we were unable to assess this statistically, since
there were no direct and indirect results for any of the comparisons.
All the trials were at unclear or high risk of bias, and the overall quality of evidence was low or very low for all outcomes. One death
occurred in the endoscopic drainage group (1/44; 2.3%), due to bleeding. There were no deaths in the other groups. The differences in
the serious adverse events were imprecise. Short-term health-related quality of life (HRQoL; four weeks to three months) was worse (MD
-21.00; 95% CI -33.21 to -8.79; participants = 40; studies = 1; range: 0 to 100; higher score indicates better) and the costs were higher in the
open surgical drainage group than the EUS-guided drainage group (MD 8040 USD; 95% CI 3020 to 13,060; participants = 40; studies = 1).
There were fewer adverse events in the EUS-guided drainage with nasocystic drainage group than in the EUS-guided drainage alone (OR
0.20; 95% CI 0.06 to 0.73; participants = 47; studies = 1), or the endoscopic drainage group (indirect comparison: OR 0.08; 95% CI 0.01 to
0.61). Participants with EUS-guided drainage with nasocystic drainage also had shorter hospital stays compared to EUS-guided drainage
alone (MD -8.10 days; 95% CI -9.79 to -6.41; participants = 47; studies = 1), endoscopic drainage (indirect comparison: MD -7.10 days; 95% CI
-9.38 to -4.82), or open surgical drainage group (indirect comparison: MD -12.30 days; 95% CI -14.48 to -10.12). The open surgical drainage
group had longer hospital stays than the EUS-guided drainage group (MD 4.20 days; 95% CI 2.82 to 5.58; participants = 40; studies = 1);
the endoscopic drainage group had longer hospital stays than the open drainage group (indirect comparison: -5.20 days; 95% CI -7.26 to
-3.14). The need for additional invasive interventions was higher for the endoscopic drainage group than the EUS-guided drainage group
(OR 11.13; 95% CI 2.85 to 43.44; participants = 89; studies = 2), and the open drainage group (indirect comparison: OR 23.69; 95% CI 1.40 to
400.71). The differences between groups were imprecise for the other comparisons that could be performed. None of the trials reported
long-term mortality, medium-term HRQoL (three months to one year), long-term HRQoL (longer than one year), time-to-return to normal
activities, or time-to-return to work.
Authors' conclusions
Very low-quality evidence suggested that the differences in mortality and serious adverse events between treatments were imprecise. Low-
quality evidence suggested that short-term HRQoL (four weeks to three months) was worse, and the costs were higher in the open surgical
drainage group than in the EUS-guided drainage group. Low-quality or very low-quality evidence suggested that EUS-guided drainage
with nasocystic drainage led to fewer adverse events than EUS-guided or endoscopic drainage, and shorter hospital stays when compared
to EUS-guided drainage, endoscopic drainage, or open surgical drainage, while EUS-guided drainage led to shorter hospital stays than
open surgical drainage. Low-quality evidence suggested that there was a higher need for additional invasive procedures with endoscopic
drainage than EUS-guided drainage, while it was lower in the open surgical drainage than in the endoscopic drainage group.
Further RCTs are needed to compare EUS-guided drainage, with or without nasocystic drainage, in symptomatic patients with pancreatic
pseudocysts that require treatment. Future trials should include patient-oriented outcomes such as mortality, serious adverse events,
HRQoL, hospital stay, return-to-normal activity, number of work days lost, and the need for additional procedures, for a minimum fol-
low-up period of two to three years.
P L A I N   L A N G U A G E   S U M M A R Y
Treatment methods for people with pancreatic pseudocysts (fluid collections around the pancreas)
Review question
How should people with pancreatic pseudocysts be treated?
Background
The pancreas is an abdominal organ that secretes several digestive enzymes (substances that enable and speed up chemical reactions in
the body) into the pancreatic ductal system, which empties into the small bowel. It also contains the Islets of Langerhans, which secrete
several hormones, including insulin (that helps to regulate blood sugar). Pancreatic pseudocysts are fluid collections around the pancreas.
They arise due to sudden or long-standing inflammation of the pancreas. While some will disappear when the inflammation of the pan-
creas settles down, others remain and cause symptoms such as abdominal pain, indigestion, vomiting, and weight loss. Treatments of
pancreatic pseudocysts include conservative treatment (watchful monitoring), surgical drainage, which can be performed through a stan-
dard cut (open surgical drainage) or by key-hole surgery (laparoscopic surgical drainage), or endoscopic drainage. In endoscopic drainage,
a tube (stent) is inserted with the help of an endoscope (a tube passed through the mouth into the stomach, usually to visualise the ab-
dominal organs from inside the body), that connects the pseudocyst to the stomach or the upper part of the small intestine. The insertion
may be further helped by using an endoscopic ultrasound (an ultrasound probe attached to the endoscope; EUS-guided drainage). Endo-
scopic ultrasound-guided drainage may be further assisted by passing a tube through the nose and inserting it into the cyst during EUS-
guided drainage (EUS-guided drainage with nasocystic drainage). The best way to treat pancreatic pseudocysts is not clear. We sought
to resolve this by searching for existing studies on the topic. We included all randomised controlled trials whose results were reported
up to 8 September 2015. Apart from using standard Cochrane methods, which allow comparison of only two treatments at a time (direct
comparison), we used advanced methods, which allow individual comparison of the different treatments compared in the trials (indirect
comparison).
Study characteristics
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We included four trials, with 177 participants, in the review, 176 of whom were included in the analyses. The treatments compared in the
four trials included endoscopic drainage (without EUS guidance), EUS-guided drainage, EUS-guided drainage with nasocystic drainage,
and open surgical drainage. The participants were mostly people with pancreatic pseudocysts resulting from sudden onset or long-term
inflammation of the pancreas, from different causes.
Key results
One death occurred in the endoscopic drainage group, due to bleeding. The differences in the serious complications were imprecise. Short-
term health-related quality of life (HRQoL; four weeks to three months) was worse, and the costs were higher in the open surgical drainage
group than in the EUS-guided drainage group. There were fewer complications of any severity (such as bleeding) that required addition-
al treatment in the EUS-guided drainage with nasocystic drainage group than in the EUS-guided drainage alone or endoscopic drainage
groups. Those who received EUS-guided drainage with nasocystic drainage also had a shorter hospital stay compared to those who re-
ceived EUS-guided drainage alone, endoscopic drainage, or open surgical drainage. Those who received EUS-guided drainage alone had
shorter hospital stays than those with open surgical drainage. There was a higher need for additional invasive treatments to completely
drain the pseudocyst with endoscopic drainage than EUS-guided drainage alone. The differences for the other comparisons were impre-
cise. None of the trials reported long-term deaths, medium-term or long-term HRQoL, time-to-return to normal activities, or time-to-re-
turn to work.
Quality of the evidence
The overall quality of evidence was low or very low for all the outcomes, because the trials were small and at high risk of bias (for exam-
ple, prejudice of people who conduct the trial, and trial participants who prefer one treatment over another). As a result, further studies
are required on this topic. Such studies should compare EUS-guided drainage with or without nasocystic drainage in people who have
symptoms from their pancreatic pseudocysts and need treatment. Such trials should measure patient-oriented outcomes for a minimum
follow-up period of two to three years.
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Summary of findings for the main comparison.   Management strategies for pancreatic pseudocysts: primary outcomes
Management strategies for pancreatic pseudocysts: a network meta-analysis
Patient or population: patients with pancreatic pseudocysts
Settings: secondary or tertiary care
Intervention: management strategies for pancreatic pseudocysts
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
EUS-guided
drainage
Other methods of
drainage
Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Short-term mortality
Endoscopic drainage versus EUS-
guided drainage
1 per 1000 3 per 1000
(0 to 74)
OR 3 
(0.11 to 79.91)
89
(2 studies)
⊕⊝⊝⊝
very low1,2,3
EUS-guided drainage with naso-
cystic drainage versus EUS-guid-
ed drainage
not estimable since there was no short-term
mortality in either group
Not estimable 47
(1 study)
⊕⊝⊝⊝
very low1,2,3
Open surgical drainage versus
EUS-guided drainage
not estimable since there was no short-term
mortality in either group
Not estimable 40
(1 study)
⊕⊝⊝⊝
very low1,2,3
Serious adverse events
Endoscopic drainage versus EUS-
guided drainage
31 per 1000 72 per 1000
(16 to 268)
OR 2.42 
(0.51 to 11.46)
89
(2 studies)
⊕⊝⊝⊝
very low1,2,3
Open surgical drainage versus
EUS-guided drainage
31 per 1000 208 per 1000
(13 to 845)
OR 8.2 
(0.4 to 169.9)
40
(1 study)
⊕⊝⊝⊝
very low1,2,3
Health-related quality of life (4 weeks to 3 months)
Open surgical drainage versus
EUS-guided drainage
Scale from: 0 to 100.
Higher indicates better
The mean health-
related quality
of life in the EUS-
guided drainage
was
The mean health-relat-
ed quality of life in the
open surgical drainage
was
21 lower
  40
(1 study)
⊕⊕⊝⊝
low1,2
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71.4 (33.21 to 8.79 lower)
• Serious adverse events were not reported for the comparison of EUS-guided drainage with nasocystic drainage versus EUS-guided drainage.• Health-related quality of life (4 weeks to 3 months) was not reported for the comparisons of EUS-guided drainage with nasocystic drainage versus EUS-guided drainage
and open surgical drainage versus EUS-guided drainage.• None of the trials reported long-term mortality, health-related quality of life at 3 months to 1 year, or health-related quality of life at more than one year.
*The basis for the assumed risk was the mean control group proportion for all outcomes other than short-term mortality. For short-term mortality, a short-term mortality of
0.1% was used since there was no mortality in the control group. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison
group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Risk of bias was unclear or high in the trial(s).
2 Sample size was small.
3 Confidence intervals overlapped clinically important differences.
 
 
Summary of findings 2.   Management strategies for pancreatic pseudocysts: a network meta-analysis
Management strategies for pancreatic pseudocysts: a network meta-analysis
Patient or population: patients with pancreatic pseudocysts
Settings: secondary or tertiary care
Intervention: management strategies for pancreatic pseudocysts
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
EUS-guided drainage Other methods of drainage
Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Adverse events
Endoscopic drainage versus EUS-
guided drainage
171 per 1000 333 per 1000
(95 to 703)
OR 2.42 
(0.51 to 11.46)
89
(2 studies)
⊕⊝⊝⊝
very low1,2,3
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EUS-guided drainage with naso-
cystic drainage versus EUS-guid-
ed drainage
171 per 1000 40 per 1000
(12 to 131)
OR 0.2 
(0.06 to 0.73)
47
(1 study)
⊕⊕⊝⊝
low1,2
Open surgical drainage versus
EUS-guided drainage
171 per 1000 698 per 1000
(104 to 979)
OR 11.18 
(0.56 to 222.98)
40
(1 study)
⊕⊝⊝⊝
very low1,2,3
Hospital stay
Endoscopic drainage versus EUS-
guided drainage
The median hospital
stay in the EUS-guided
drainage group was
2.65 days
The mean hospital stay in the en-
doscopic drainage was 1 day less
(2.53 less to 0.53 higher)
  29
(1 study)
⊕⊝⊝⊝
very low1,2,3
EUS-guided drainage with naso-
cystic drainage versus EUS-guid-
ed drainage
The median hospital
stay in the EUS-guided
drainage group was
2.65 days
The mean hospital stay in the
EUS-guided drainage with naso-
cystic drainage was
8.1 days less (9.79 to 6.41 less)
  47
(1 study)
⊕⊕⊝⊝
low1,2
Open surgical drainage versus
EUS-guided drainage
The median hospital
stay in the EUS-guided
drainage group was
2.65 days
The mean hospital stay in the
open surgical drainage was 4.2
days more
(2.82 to 5.58 more)
  40
(1 study)
⊕⊕⊝⊝
low1,2
Need for additional drainage
Endoscopic drainage versus EUS-
guided drainage
62 per 1000 424 per 1000
(159 to 742)
OR 11.13 
(2.85 to 43.44)
89
(2 studies)
⊕⊝⊝⊝
very low1,2,4
Open surgical drainage versus
EUS-guided drainage
62 per 1000 30 per 1000
(3 to 273)
OR 0.47 
(0.04 to 5.69)
40
(1 study)
⊕⊝⊝⊝
very low1,2,3
Costs
Open surgical drainage versus
EUS-guided drainage
The mean costs in the
EUS-guided drainage
were
7010 US dollars
The mean costs in the open surgi-
cal drainage were 8040 higher 
(3020 to 13,060 higher)
  40
(1 study)
⊕⊕⊝⊝
low1,2
• Need for additional drainage was not reported for the comparison of EUS-guided drainage with nasocystic drainage versus EUS-guided drainage.• Costs were not reported for the comparisons of EUS-guided drainage with nasocystic drainage versus EUS-guided drainage and open surgical drainage versus EUS-guided
drainage.• None of the trials reported time-to-return to normal activity, or time-to-return to work.
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*The basis for the assumed risk was the mean control group proportion. The corresponding risk (and its 95% confidence interval) was based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Risk of bias was unclear or high in the trial(s).
2 Sample size was small.
3 Confidence intervals overlapped clinically important differences.
4 There was moderate inconsistency as evidenced by I-square, tau-square, and lack of significant overlap of confidence intervals.
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B A C K G R O U N D
Description of the condition
The pancreas is an abdominal organ that secretes several diges-
tive enzymes into the pancreatic ductal system that empties into
the small bowel. It also lodges the Islets of Langerhans, which se-
crete several hormones, including insulin (NCBI 2014). Pancreatic
pseudocysts are fluid collections in the peripancreatic tissues, al-
though they may be partly or wholly intra-pancreatic (Banks 2013).
They are surrounded by a well-defined wall and contain only flu-
id, with little or no solid material (Banks 2013). They can arise af-
ter an episode of acute pancreatitis, sudden worsening of chron-
ic pancreatitis, or pancreatic trauma (Cannon 2009). However, the
development of a pancreatic pseudocyst is rare in acute pancreati-
tis (Banks 2013). Most fluid collections previously called pseudo-
cysts after an episode of acute pancreatitis are now called acute
peripancreatic fluid collections (which do not have well-defined
walls), acute necrotic collections (which do not contain a wall and
contain solid material because of necrosis), or walled-oG necro-
sis (which have solid material because of necrosis; Banks 2013).
Pancreatic pseudocysts are believed to arise from a disruption of
the main pancreatic duct or its branches without any recognisable
pancreatic parenchymal (pancreatic cellular tissue) necrosis (indi-
cated by solid necrotic material), resulting in leakage of pancre-
atic juice into the retroperitoneum or the peripancreatic tissues,
which leads to a persistent, localised fluid collection (Banks 2013;
Cannon 2009). Occasionally, a pseudocyst may also arise in people
with acute necrotising pancreatitis (inflammation of the pancreas
with presence of necrosis in the pancreas or peripancreatic tissues)
when the pancreatic parenchymal necrosis of the neck or body of
the pancreas isolates a still-functioning distal (leK-sided) pancreat-
ic remnant (‘disconnected duct syndrome’; Banks 2013). Rarely, a
pseudocyst may be evident many weeks after surgical debridement
(removal of necrotic tissue) for acute pancreatic necrosis (necro-
sectomy), due to localised leakage of the disconnected duct into
the necrosectomy cavity. Since the necrosis has been removed, the
walled-oG cavity contains only fluid and hence, is called a pseudo-
cyst (Banks 2013). The pancreatic pseudocystic fluid is usually rich
in pancreatic amylase (Banks 2013; Cannon 2009). Diagnoses of
pancreatic pseudocysts are made on the basis of the presence of
cystic collection in the peripancreatic tissues with a well-defined
wall and with little or no solid material on an imaging modality,
such as contrast-enhanced computed tomography (CECT), mag-
netic resonance imaging (MRI), or an ultrasound (Banks 2013).
The true incidence of pancreatic pseudocysts is difficult to deter-
mine, because many of the previous studies calculating the inci-
dence in acute pancreatitis might have included acute peripan-
creatic fluid collections, acute necrotic collections, or walled-oG
necrosis. Symptoms related to pancreatic pseudocysts include per-
sistent abdominal pain, gastric (stomach) outlet obstruction, jaun-
dice (yellowish discolouration of the skin and dark urine), dyspep-
sia (indigestion), weight loss, and persistent fevers. They are be-
lieved to arise from the local mass effect (pressure on the sur-
rounding structures) of the pseudocyst or the associated inflam-
matory response (Cannon 2009; Cheruvu 2003). Potential com-
plications related to pancreatic pseudocysts include infection of
the pseudocyst, bile duct or gastric outflow obstruction, free rup-
ture of the pseudocyst into the peritoneal cavity, portal or splenic
vein thrombosis leading to sinistral (leK-sided) portal hyperten-
sion, pseudocyst erosion into adjacent (nearby) vessels resulting in
pseudoaneurysm formation, or even catastrophic haemorrhage in-
to the gastrointestinal tract or peritoneal cavity (Cannon 2009; Vitas
1992). However, the frequency of these complications is not known,
since the natural history of pancreatic pseudocysts is not well un-
derstood (Cannon 2009).
See Appendix 1 for a glossary of terms.
Description of the intervention
The main purpose of treatment is for the relief of symptoms re-
lated to pancreatic pseudocysts and to avoid the complications
related to pseudocysts. The various treatment options include:
conservative management; surgical management (cystogastros-
tomy or cystoenterostomy); radiological management (percuta-
neous drainage); endoscopic management (transpapillary), when
the pancreatic pseudocyst communicates with the main pancreat-
ic duct, transenteric approach, when an endoluminal bulge (with-
in the cavity of the stomach or small intestine), or endoscopic ul-
trasound evidence of adherence between the gastric or duode-
nal wall and the cyst without associated necrosis, which can be
achieved with or without an endoscopic ultrasound and with or
without nasocystic drainage; Cannon 2009; Cheruvu 2003; John-
son 2009; Varadarajulu 2008; Varadarajulu 2013; Yuan 2015). Some
of the treatment-related complications include bleeding that re-
quires additional treatment, and pancreatic stricture (Varadarajulu
2008; Varadarajulu 2013).
How the intervention might work
The interventions may work by decompressing the fluid, reliev-
ing the pressure of the pancreatic pseudocyst on the surrounding
structures, relieving the inflammatory response that causes symp-
toms, and allowing an alternative route for the pancreatic juice
to reach the small bowel, thereby allowing digestion and relieving
pain that arises because of indigestion.
Why it is important to do this review
Currently, treatment of pseudocysts is only indicated in symp-
tomatic patients (Cannon 2009). The traditional management of
symptomatic pancreatic pseudocysts is open surgical drainage.
The roles of laparoscopic drainage, endoscopic drainage using an
oesophagoduodenoscope or an endoscopic ultrasound, percuta-
neous management, and conservative management are not clear.
Multiple treatment comparison or network meta-analysis allows
the comparison of several treatments simultaneously and provides
information on the relative effect of one treatment versus anoth-
er, even when no direct comparison has been made. There is no
Cochrane network meta-analysis on this topic. This systematic re-
view and network meta-analysis will identify the relative effects of
different treatments and identify any research gaps.
O B J E C T I V E S
To assess the benefits and harms of different management strate-
gies for pancreatic pseudocysts.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs). We included stud-
ies reported as full text, those published as abstract only, and un-
published data.
Types of participants
We included adults with pancreatic pseudocysts, regardless of the
cause for the pseudocyst (acute pancreatitis, chronic pancreatitis,
or trauma), the presence of symptoms, or the size and location of
the cyst.
When an incidental pancreatic cyst is noted (i.e., people undergo a
scan for other reasons and a pancreatic cyst is noted), there may
be difficulty in distinguishing a pancreatic pseudocyst, arising in
the background of chronic pancreatitis, from pancreatic cystic neo-
plasms (premalignant or malignant) that may cause local inflam-
mation (Cannon 2009). Sometimes, it may not be possible to estab-
lish a clear diagnosis based on additional imaging, cytology of the
fluid, or tumour marker levels in the fluid (Cannon 2009). In such
situations, resection of the cyst and histopathological examination
(examination under the microscope) may be performed purely to
ensure that premalignant or malignant lesions are not missed. We
excluded such participants from this review as they were not our
main focus.
Types of interventions
We had planned to include trials comparing any of the following in-
terventions with another intervention in the list, provided that the
only difference between the randomised groups was the manage-
ment intervention or interventions being assessed.
1. Open surgical drainage;
2. Laparoscopic surgical drainage;
3. Percutaneous radiological drainage;
4. Endoscopic drainage;
5. Endoscopic drainage with guidance from endoscopic ultra-
sound (EUS-guided drainage);
6. EUS-guided drainage with nasocystic drainage;
7. Conservative management.
Types of outcome measures
Primary outcomes
1. Mortality.
a. Short-term mortality (in-hospital mortality or mortality with-
in three months);
b. Long-term mortality (at maximum follow-up).
2. Serious adverse events (within three months). We accepted the
following definitions of serious adverse events:
a. International Conference on Harmonisation - Good Clinical
Practice guideline (ICH-GCP 1996): Serious adverse events,
defined as any untoward medical occurrence that results in
death, is life-threatening, requires inpatient hospitalisation
or prolongation of existing hospitalisation, results in persis-
tent or significant disability, incapacity, or both;
b. Other variations of ICH-GCP classifications such as Food and
Drug Administration (FDA) classification (FDA 2006), Medi-
cines and Healthcare products Regulatory Agency (MHRA)
classification (MHRA 2013);
c. Clavien-Dindo classification (Clavien 2009; Dindo 2004):
Grade III or more;
d. Individual complications that could be clearly classified as
Grade III or more with Clavien-Dindo classification or as a se-
rious adverse event with ICH-GCP classification.
3. Health-related quality of life (HRQoL), using any validated scale.
a. Short-term (four weeks to three months);
b. Medium-term (three months to one year);
c. Long-term (longer than one year).
Secondary outcomes
1. Adverse events (within three months). We accepted all adverse
events reported by the study author regardless of the severity of
the event.
2. Measures of decreased complications and earlier recovery
(within three months).
a. Length of hospital stay (including the index admission for in-
tervention and any disease-related or intervention-related
readmissions);
b. Time-to-return to normal activity (return to pre-intervention
mobility without additional caregiver support);
c. Time-to-return to work (for those who were previously em-
ployed).
3. Need for additional invasive intervention, such as drainage or re-
operation in the case of surgical interventions, and redrainage
or surgical intervention in the case of other interventions (long-
term).
4. Costs (within three months).
The choice of these clinical outcomes is based on the necessity to
assess whether the interventions are safe and effective in the treat-
ment of pancreatic pseudocysts. The costs provide an indication of
resource requirement.
We did not regard the reporting of the outcomes listed here as an
inclusion criterion for the review.
Search methods for identification of studies
Electronic searches
We conducted a literature search to identify all published and un-
published randomised controlled trials in all languages. We had
planned to translate the non-English language papers and fully as-
sess them for potential inclusion in the review as necessary.
We searched the following electronic databases:
• Cochrane Central Register of Controlled Trials (CENTRAL; The
Cochrane Library 2015, Issue 9; Appendix 2);• MEDLINE (1966 to September 2015; Appendix 3);• EMBASE (1988 to September 2015; Appendix 4); and• Science Citation Index (1982 to September 2015; Appendix 5).
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We also searched ClinicalTrials.gov (Appendix 6) and the World
Health Organization International Clinical Trials Registry Platform
(WHO ICTRP) on 8 September 2015 (Appendix 7).
Searching other resources
We checked reference lists of all primary studies and review articles
for additional references. We attempted to contact authors of iden-
tified trials and asked them to identify other published or unpub-
lished studies.
We searched for errata or retractions from eligible trials
www.ncbi.nlm.nih.gov/pubmed on 4 January 2016.
Data collection and analysis
Selection of studies
Two review authors (KG and EP) independently screened titles and
abstracts of all the potential studies we identified, and coded them
as 'retrieve' (eligible or potentially eligible or unclear) or 'do not
retrieve'. We retrieved the full-text study reports, and two review
authors (KG and EP) independently screened them and identified
studies for inclusion; we identified and recorded reasons for exclu-
sion of the ineligible studies. We resolved disagreements through
discussion. We identified and excluded duplicates, and collated
multiple reports of the same study, so that each study, rather than
each report, was the unit of interest in the review. We had planned
to contact the authors of trials of unclear eligibility. We recorded
the selection process in sufficient detail to complete a PRISMA flow
diagram and a 'Characteristics of excluded studies' table.
Data extraction and management
We used a standard data collection form for study characteristics
and outcome data, which had been piloted on at least one study in
the review. Two review authors (KG and EP) extracted the following
study characteristics:
1. Methods: study design, total duration of study and run in, num-
ber of study centres and location, study setting, withdrawals,
date of study.
2. Participants: number (N), mean age, age range, gender, pres-
ence of symptoms, average size of the pancreatic pseudocyst,
inclusion criteria, exclusion criteria.
3. Interventions: intervention, comparison, concomitant interven-
tions, number of participants randomised to each group.
4. Outcomes: primary and secondary outcomes specified and col-
lected, time points reported. For binary outcomes, we obtained
the number of participants with events and the number of par-
ticipants included in the analysis in each group. For continu-
ous outcomes, we obtained the unit or scale of measurement,
mean, standard deviation, and the number of participants in-
cluded in the analysis for each group. For count outcomes, we
had planned to obtain the number of events and the number
of participants included in the analysis in each group. For time-
to-event outcomes, we had planned to obtain the proportion of
people with events, the average duration of follow-up of partici-
pants in the trial, and the number of participants included in the
analysis for each group.
5. Notes: funding for trial, notable conflicts of interest of trial au-
thors.
Two review authors (KG and EP) independently extracted outcome
data from the included studies. If outcomes had been reported at
multiple time points, we would have extracted the data for all time
points. We obtained information on the number of participants
with adverse events (or serious adverse events) and the number of
such events, where applicable. We extracted costs, using the cur-
rency reported by trial authors and had planned to convert them to
US dollars at the conversion rates on the day of the analyses. We ex-
tracted data for every trial arm that was an included intervention.
If outcome data were reported in an unusable way, we attempted
to contact the trial authors to obtain usable data. If we were unable
to obtain usable data, we had planned to summarise the unusable
data in an appendix. We resolved disagreements by consensus. One
review author (KG) copied the data from the data collection form
into the Review Manager 5 file. We double-checked that the data
were entered correctly by comparing the study reports with the da-
ta in the systematic review.
Assessment of risk of bias in included studies
Two review authors (KG and EP) independently assessed the risk
of bias for each study, using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions  (Higgins 2011).
We resolved disagreement by discussion. We assessed the risk of
bias according to the following domains:
1. Random sequence generation;
2. Allocation concealment;
3. Blinding of participants and personnel;
4. Blinding of outcome assessment;
5. Incomplete outcome data;
6. Selective outcome reporting;
7. Other potential bias.
We classified each potential source of bias as high, low, or unclear,
and provided a quote from the study report, together with a justifi-
cation for our judgement, in the 'Risk of bias' table. We summarised
the risk of bias judgements across all studies for each of the do-
mains listed. We had planned to consider blinding separately for
different key outcomes where necessary, e.g., for unblinded out-
come assessment, risk of bias for all-cause mortality may be very
different than for a participant-reported pain scale. Where informa-
tion on risk of bias related to unpublished data or to correspon-
dence with a trial author, we had planned to note this in the 'Risk of
bias' table. We had planned to present the risk of bias in each pair-
wise comparison in separate tables. However, there were only four
trials and all the trials were considered to be at unclear or high risk
of bias, so, we did not present this information.
When considering treatment effects, we took into account the risk
of bias for the studies that contributed to that outcome by complet-
ing a sensitivity analysis.
Assesment of bias in conducting the systematic review
We conducted the review according to the published protocol, and
have reported any deviations from it in the 'Differences between
protocol and review' section of the review (Gurusamy 2014).
Measures of treatment e>ect
For dichotomous variables, such as short-term mortality, propor-
tion of participants with adverse events, requirement for addition-
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al interventions, we planned to calculate the odds ratio (OR) with a
95% credible interval (CrI). For continuous variables, such as length
of hospital stay, time-to-return to normal activity, time-to-return
to work, and costs, we had planned to calculate the mean differ-
ence (MD) with a 95% CrI. We had planned to use the standardised
mean difference (SMD) with a 95% CrI for quality of life if different
scales were used. For count outcomes, such as the number of ad-
verse events, we had planned to calculate the rate ratio (RaR) with
a 95% CrI. For time-to-event data, such as long-term mortality, and
a requirement for additional invasive intervention, such as reop-
eration in the case of surgical interventions, and surgical interven-
tion in the case of other interventions, we had planned to use the
hazard ratio (HR) with a 95% CrI. However, we did not perform a
Bayesian network analysis and performed a simple indirect com-
parison using frequentist methods. So, we calculated the above
treatment effects when data was available with 95% confidence in-
tervals. Please see 'Data synthesis' for the reason for not perform-
ing the network meta-analysis.
A common way that trial authors indicate that they have skewed
data is by reporting medians and interquartile ranges. When we
encountered this, we had planned to report the median and in-
terquartile range in a table.
Unit of analysis issues
The unit of analysis was individual participants with a pancreatic
pseudocyst. As anticipated, there were no cluster-randomised tri-
als for this comparison, but if we had identified any, we had planned
to obtain the effect estimate adjusted for the clustering effect. If this
was not available from the report or from the trial authors, we had
planned to exclude the trial from the meta-analysis.
In multi-arm trials, the models account for the correlation between
trial-specific treatment effects from the same trial.
Dealing with missing data
We attempted to contact investigators or study sponsors in order
to verify key study characteristics, and obtain missing numerical
outcome data, where possible (e.g., when a study was identified as
an abstract only). For binary, count, and time-to-event outcomes,
we had planned to perform an intention-to-treat analysis whenever
possible (Newell 1992). If this was not possible, we would have per-
formed an available-case analysis, but had planned to assess the
impact of 'best-best', 'best-worst', 'worst-best', 'worst-worst' sce-
nario analyses on the results for binary outcomes. For continuous
outcomes, we performed an available-case analysis. if we were un-
able to obtain the information from the investigators or study spon-
sors, we imputed the mean from the median (i.e., considered the
median as the mean) and the standard deviation from the standard
error, interquartile range, or P values, according to the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011);
we assessed the impact of including such studies in a sensitivity
analysis, as indicated. If we had been unable to calculate the stan-
dard deviation from the standard error, inter-quartile range, or P
values, we had planned to impute the standard deviation as the
highest standard deviation in the remaining trials included in the
outcome, being fully aware that this method of imputation would
decrease the weight of the studies in the meta-analysis of mean dif-
ference and that it would shiK the effect towards no effect for stan-
dardised mean difference. We had planned to assess the impact of
including such studies by performing sensitivity analyses.
Assessment of heterogeneity
We assessed the heterogeneity in each pair-wise comparison by as-
sessing the Higgins I2 (Higgins 2003), the Chi2 test with significance
set at a P value less than 0.10, and visual inspection, whenever ap-
plicable. We also used the Tau2 statistic to measure heterogeneity
among the trials in each analysis. The Tau2 statistic provides a mea-
sure of the variability of the effect estimate across studies in a ran-
dom-effects model (Higgins 2011). If we had identified substantial
heterogeneity, we had planned to explore it by performing a meta-
regression.
Assessment of reporting biases
We attempted to contact trial authors, asking them to provide miss-
ing outcome data. Where this was not possible, and the missing da-
ta were thought to introduce serious bias, we had planned to ex-
plore the impact of including such studies in the overall assessment
of results with a sensitivity analysis.
If we had been able to pool more than 10 trials for a specific com-
parison, we had planned to create and examine a funnel plot to ex-
plore possible publication bias. We had planned to use Egger's test
to determine the statistical significance of the reporting bias (Egger
1997). We had planned to consider a P value of less than 0.05 sta-
tistically significant of reporting bias.
Data synthesis
We undertook meta-analyses only where this was meaningful, i.e.,
if the treatments, participants and the underlying clinical question
were similar. In general, we favoured performing a meta-analysis,
and had planned to clearly highlight the reason for not performing
one if we decided against it. We had planned to conduct network
meta-analyses to compare multiple interventions simultaneously
for each of the primary and secondary outcomes whenever applic-
able. Network meta-analysis combines direct evidence within trials
and indirect evidence across trials (Mills 2012).
We had planned to obtain network plots to ensure that the trials
were connected by treatments using Stata/IC 11 (StataCorp LP;
please see Appendix 8 for the Stata command we had planned to
use). We had planned to apply network meta-analysis to each con-
nected network, and conduct a Bayesian network meta-analysis
using the Markov chain Monte Carlo method in WinBUGS 1.4. We
had planned to model the treatment contrast (e.g., log OR for bina-
ry outcomes and MD for continuous outcomes) for any two inter-
ventions ('functional parameters') as a function of comparisons be-
tween each individual intervention and an arbitrarily selected ref-
erence group ('basic parameters'; Lu 2004). We had planned to use
EUS-guided drainage as the reference group. We had planned to
perform the network analysis as per the guidance from the Nation-
al Institute for Health and Clinical Excellence Decision Support Unit
(NICE DSU) documents (Dias 2013).
Further details of the codes used and the technical details of how
we planned to perform the analysis are shown in Appendix 9 and
Appendix 10. In short, we had planned to use three non-informa-
tive priors, a burn-in of 30,000 simulations to ensure convergence
(we planned to use longer burn-in if the models did not converge
in 30,000 simulations), and obtain the posterior estimates after a
further 100,000 simulations. We had planned to use the fixed-effect
and random-effects models (assuming homogeneous between-tri-
al variance across comparisons) for each outcome. We had planned
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to choose the fixed-effect model if results were an equivalent or
better fit (assessed by residual deviances, number of effective pa-
rameters, and deviance information criterion (DIC)) than the ran-
dom-effects model. A lower DIC indicates a better model fit. We had
planned to use the random-effects model if it resulted in a better
model fit, as indicated by a DIC lower than that of the fixed-effect
model by at least three. In addition, we had planned to perform a
treatment-by-design random-effects inconsistency model (Higgins
2012; White 2012). We had planned to consider that the inconsisten-
cy model was a better model than the random-effects consistency
model (standard random-effects network meta-analysis model) if
the model fit of the inconsistency model (as indicated by the DIC)
was at least three lower than the random-effects consistency mod-
el.
For multi-arm trials, one can enter the data from all arms in a trial.
This is entered as the number of people with events and the number
of people exposed to the event, using the binomial likelihood and
logit link for binary outcomes; the mean and standard error using
the normal likelihood and identity link for continuous outcomes re-
quiring calculation of the mean difference; the mean and standard
error of the treatment differences using the normal likelihood and
identity link for continuous outcomes requiring calculation of the
standardised mean difference; the number of events and the num-
ber of people exposed to the event using the Poisson likelihood and
log link for count outcomes; and follow-up time in the study, num-
ber of people with the event and the number of people exposed to
the event using the binomial likelihood and cloglog link for time-
to-event outcomes. However, we did not encounter any multi-arm
trials.
We had planned to report the treatment contrasts (e.g., log ORs
for binary outcomes and MDs for continuous outcomes) of the dif-
ferent treatments in relation to the reference treatment (i.e., EUS-
guided drainage), the residual deviances, the number of effective
parameters, and the DIC for a fixed-effect model and a random-ef-
fects model for each outcome. We had also planned to report the
parameters used to assess the model fit (i.e., residual deviances,
number of effective parameters, and DIC) for the inconsistency
model for all the outcomes, and the between-trial variance for the
random-effects model (Dias 2012a; Dias 2012b; Higgins 2012; White
2012). If the inconsistency model had resulted in a better model fit
than the consistency models, the transitivity assumption was like-
ly to be untrue and the effect estimates obtained may not have be
reliable. We had planned to highlight such outcomes where the in-
consistency model resulted in a better model fit than the consisten-
cy models. We had planned to perform a separate network meta-
analysis for different subgroups to assess the inconsistency again.
If there was no evidence of inconsistency in the revised analysis, we
had planned to present the results of the analysis for different sub-
groups separately. If there was persistent evidence of inconsisten-
cy, we had planned to present the results from the direct compari-
son in the 'Summary of findings' table.
We had planned to calculate the 95% CrIs of treatment effects (e.g.
ORs for binary outcomes, MDs for continuous outcomes, and so
on) in the Bayesian meta-analysis, which is similar in use to the
95% confidence intervals in the Frequentist meta-analysis. These
are the 2.5th percentile and 97.5th percentiles of the simulations.
We had planned to report the mean effect estimate and the 95%
CrI for each pair-wise comparison in a table. We had also planned
to estimate the probability that each intervention ranked at one of
the possible positions and would have presented this information
in graphs. It should be noted that one should not conclude that a
treatment is the best one for an outcome if the probability of be-
ing the best is less than 90% (Dias 2012a). We had also planned
to present the cumulative probability of the treatment ranks (i.e.,
the probability that the treatment is within the top two, the top
three, etc.) in graphs. We had also planned to plot the probability
that each treatment was best for each of the different outcomes
(rankograms), which are generally considered more informative
(Dias 2012a; Salanti 2011). However, because of sparse data, tri-
als with zero events and lack of direct and indirect evidence for
any comparisons, we only performed indirect comparisons, using
methods described by Bucher, et al (Bucher 1997). Although we had
planned to perform the direct comparisons using the same codes,
we used the RevMan statistical algorithm for direct comparisons,
which allowed us to present information in the standard Cochrane
way.
In the presence of adequate data, where authors reported the out-
comes of participants at multiple follow-up time points, we had
planned to follow the methods suggested by Lu 2007 to perform the
meta-analysis.
'Summary of findings' table
We created a 'Summary of findings' table that reported on all the
outcomes. We used the five GRADE considerations (study limita-
tions, consistency of effect, imprecision, indirectness and publica-
tion bias) to assess the quality of the body of evidence as it re-
lated to the studies that contributed data to the meta-analyses
for the prespecified outcomes. We had planned to use methods
and recommendations described in the GRADE Working Group ap-
proach for rating the quality of treatment effect estimates from
network meta-analysis (Puhan 2014). However, since the network
meta-analysis was not performed, we only presented the results of
direct and indirect comparisons. We justified all decisions to down-
or upgrade the quality rating of the evidence using footnotes, and
made comments to aid the reader's understanding of the review
where necessary. We considered whether there was any addition-
al outcome information that we were not able to incorporate into
meta-analyses and noted this in the comments.
Subgroup analysis and investigation of heterogeneity
We had planned to assess the differences in the effect estimates
between the following subgroups using meta-regression, with the
help of the code shown in Appendix 6, when at least one trial was
included in each subgroup.
1. Symptomatic versus asymptomatic participants.
2. Reason for pancreatic pseudocyst (acute pancreatitis, chronic
pancreatitis, trauma).
3. Mean size of the pseudocyst. Although size is not the main rea-
son for the treatment, observational studies have found that
the mean size of pseudocysts was higher in people who re-
quired surgery after conservative management, compared to
those who did not require surgery after conservative manage-
ment (7 cm versus 5 cm) (Vitas 1992).
We had planned to calculate the interaction term (Dias 2012c). If
the 95% CrI of the interaction term did not overlap zero, we had
planned to consider this statistically significant.
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Sensitivity analysis
We had planned to perform the following sensitivity analyses de-
fined a priori to assess the robustness of our conclusions.
1. Excluding trials at unclear or high risk of bias (one or more of the
risk of bias domains classified as unclear or high).
2. Excluding trials in which either the mean, the standard devia-
tion, or both were imputed.
3. Imputation of binary outcomes under 'best-best', 'best-worst',
'worst-best', and 'worst-worst' scenarios.
Reaching conclusions
We based our conclusions only on findings from the quantitative or
narrative synthesis of included studies for this review. We avoided
making recommendations for practice, and our implications for re-
search give the reader a clear sense of the remaining uncertainties,
and where future research in this area should focus.
R E S U L T S
Description of studies
Results of the search
We identified 2467 references through electronic searches of
Cochrane (Wiley; N = 200), MEDLINE (OvidSP; N = 1262), EMBASE
(OvidSP; N = 736), Science Citation Index expanded (N = 255), Clini-
calTrials.gov (N = 1), and WHO Trials register (N = 13). After remov-
ing duplicate references, there were 2052 references remaining. We
excluded 2041 clearly irrelevant references by reading titles and ab-
stracts. One reference was identified by reference searching. The
full publication of 12 references were retrieved for further detailed
assessment. One reference was excluded since it was a comment
on an included study (Sauer 2010). One reference was an ongoing
study from the WHO ICTRP trial register (NCT02041793). Although
it appears to have completed recruitment, we were unable to find
any written record of the results. In total, ten references describing
four trials fulfilled the inclusion criteria (Characteristics of included
studies). The reference flow is shown in Figure 1.
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Figure 1.   Study flow diagram.
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Figure 1.   (Continued)
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Included studies
Four randomised controlled trials (RCT) were included in this
review; they were all two-armed trials (Park 2009; Varadarajulu
2008; Varadarajulu 2013; Yuan 2015). Three trials included only
symptomatic patients with pseudocysts (Park 2009; Varadaraju-
lu 2008; Varadarajulu 2013). This information was not available in
Yuan 2015. Two studies reported that they included patients with
pseudocysts from acute and chronic pancreatitis due to various ae-
tiologies (Park 2009; Varadarajulu 2013). However, these studies
did not report the data separately for people with acute and chronic
pancreatitis. The remaining two trials did not report information on
whether the pseudocyst was associated with acute or chronic pan-
creatitis. The mean size of the pseudocysts across studies ranged
between 70 mm and 155 mm. No separate data were available for
pseudocysts of different sizes. Infected pseudocysts were excluded
in two trials (Park 2009; Varadarajulu 2008). This information was
not available in the remaining two trials (Varadarajulu 2013; Yuan
2015).
A total of 177 participants were randomised in the four trials. One
trial excluded a participant with suspicion of a pancreatic adeno-
ma, leaving a total of 176 participants (Varadarajulu 2008). The in-
terventions and length of follow-up were as follows; all were com-
pared to EUS-guided drainage:
1. Park 2009: Endoscopic drainage (29 participants) versus EUS-
guided drainage (31 participants). Follow-up: minimum six
months.
2. Varadarajulu 2008: Endoscopic drainage (15 participants) versus
EUS-guided drainage (14 participants). Follow-up: minimum six
weeks.
3. Yuan 2015: EUS-guided drainage with nasocystic drainage (24
participants) versus EUS-guided drainage (23 participants). Fol-
low-up: minimum 24 months.
4. Varadarajulu 2013; Open surgical drainage (20 participants) ver-
sus EUS-guided drainage (20 participants). Follow-up: minimum
24 months.
Pseudocysts were drained into the stomach in two trials (Varadara-
julu 2013; Yuan 2015), and into the stomach or duodenum in two
trials (Park 2009; Varadarajulu 2008). Routine stent removal was
reported in two trials (Varadarajulu 2008; Varadarajulu 2013). In
Varadarajulu 2008, the stents were removed after six weeks in those
with successful resolution of cysts in both groups. In Varadarajulu
2013, the stents were removed after eight weeks in the EUS-guid-
ed drainage group following CT scan confirmation of the successful
resolution of the cysts. The timing of stent removal in either group
was not reported in the remaining trials.
Study details of the population, interventions, outcomes and risk
of bias are listed in the Characteristics of included studies table and
Table 1.
Excluded studies
One reference was excluded since this was a comment on an includ-
ed study (Sauer 2010).
Risk of bias in included studies
None of the included trials were at low risk of bias. The risk of bias
in the individual domains are summarised in Figure 2 and Figure 3.
 
Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 3.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
 
Allocation
Two trials reported the allocation sequence generation and alloca-
tion concealment adequately and are at low risk of selection bias
(Varadarajulu 2008; Varadarajulu 2013). The remaining trials did
not report the allocation sequence generation (Yuan 2015), or allo-
cation concealment (Park 2009) and hence are at unclear risk of se-
lection bias.
Blinding
It is not possible to blind the endoscopist or surgeons performing
the procedures. However, it is possible to blind the participants (ex-
cept for the comparison between endoscopic and surgical meth-
ods) and outcome assessors, endoscopists or surgeons who make
clinical decisions after the procedure. None of the trials reported
on blinding of the participants or outcome assessors. Hence, all the
trials were at unclear risk of performance bias and unclear risk of
detection bias for all outcomes other than mortality. All-cause mor-
tality was reported and it was unlikely that the lack of blinding in-
troduced bias in the assessment of mortality.
Incomplete outcome data
Three trials reported the participant flow clearly (Park 2009;
Varadarajulu 2008; Varadarajulu 2013). Of these, there were no
post-randomisation drop-outs in two trials (Park 2009; Varadaraju-
lu 2013). So, these two trials are at low risk of attrition bias. In one
trial, one participant randomised to EUS-guided drainage group
was excluded from analysis since the EUS revealed septae in the
cyst, leading to a suspicion of pancreatic adenoma (Varadarajulu
2008). However, identifying septae is only possible with EUS-guid-
ed drainage and is a potential advantage of the procedure. Hence,
the overall benefit of EUS-guided drainage may have been under-
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estimated. Nevertheless, the exclusion of this patient was unlikely
to result in bias for any of the reported outcomes. So, this trial was
also considered to be at low risk of attrition bias. The fourth trial
was considered to be at unclear risk of attrition bias since it did not
report the participant flow (Yuan 2015).
Selective reporting
None of the trials had a pre-published protocol. Three trials report-
ed the clinical outcomes that were likely to be measured in such
clinical trials and were considered to be at low risk of selective
reporting (Park 2009; Varadarajulu 2008; Varadarajulu 2013). Yuan
2015 did not report morbidity clearly and was considered to be at
risk of selective outcome reporting bias.
Other potential sources of bias
One trial advised they had no external funding (Varadarajulu 2013).
The source of funding in the remaining trials was not reported.
There was no other bias noted in the remaining trials.
E>ects of interventions
See: Summary of findings for the main comparison Management
strategies for pancreatic pseudocysts: primary outcomes; Summa-
ry of findings 2 Management strategies for pancreatic pseudo-
cysts: a network meta-analysis
The effects of interventions have been summarised in Summary of
findings for the main comparison and Summary of findings 2, None
of the trials reported the following outcomes: long-term mortality,
quality of life at medium-term (three months to one year) or long-
term (more than one year), time-to-return to normal activity, and
time-to-return to work.
Only one comparison (endoscopic drainage versus EUS-guided
drainage) was examined in more than one trial. So, heterogeneity
and random-effects model are only presented for this comparison,
when both trials reported the outcome (Park 2009; Varadarajulu
2008).
Primary outcomes
1. Short-term mortality
All four trials reported short-term mortality (Park 2009; Varadaraju-
lu 2008; Varadarajulu 2013; Yuan 2015). There was only one death
reported in the endoscopic drainage group, due to major bleeding
(Varadarajulu 2008). A direct comparison using the RevMan statis-
tical algorithm revealed no statistically significant difference be-
tween the EUS-guided drainage and endoscopic drainage groups
(OR 3.00; 95% CI 0.11 to 79.91; participants = 89; studies = 2; Analy-
sis 1.1). Since there was only one death in one arm of one study, a
network meta-analysis was not performed and the issues of fixed-
effect model versus random-effects model and heterogeneity did
not arise. The absolute proportions of short-term mortality in dif-
ferent interventions are as follows.
1. EUS-guided drainage 0% (0/88);
2. Endoscopic drainage 2.3% (1/44);
3. EUS-guided drainage with nasocystic drainage 0% (0/24);
4. Open surgical drainage 0% (0/20).
Long-term mortality
None of the trials reported long-term mortality.
2. Serious adverse events
Three trials (129 participants) reported serious adverse events,
which included: bleeding requiring additional intervention, pneu-
moperitoneum, stent migration, difficulty in eating requiring surgi-
cal placement of feeding tube, and pancreatic stricture requiring
distal pancreatectomy (Park 2009; Varadarajulu 2008; Varadarajulu
2013).
Direct comparison
As shown in Analysis 1.2, there were no statistically significant dif-
ferences in any of the direct comparisons (endoscopic drainage ver-
sus EUS-guided drainage: OR 2.42; 95% CI 0.51 to 11.46; partici-
pants = 89; studies = 2; open surgical drainage versus EUS-guided
drainage: OR 8.20; 95% CI 0.40 to 169.90; participants = 40; stud-
ies = 1). There was no evidence of heterogeneity in the endoscopic
drainage versus EUS-guided drainage comparison (I2 = 0; Chi2 test
for heterogeneity = 0.53), and no difference in the interpretation of
results using either the fixed-effect or random-effects models.
The absolute unadjusted proportions of people with serious ad-
verse events in different interventions were:
1. EUS-guided drainage: 3.1% (2/65);
2. Endoscopic drainage: 11.4% (5/44);
3. Open surgical drainage: 15.0% (3/20).
Indirect comparison
As shown in Figure 4, there was no statistically significant difference
in the proportion of people with serious adverse events between
endoscopic drainage and open surgical drainage (OR 0.30; 95% CI
0.01 to 8.87).
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Figure 4.   Indirect comparisons for adverse events and length of hospital stay
 
3. Health-related quality of life (HRQoL)
Short-term: four weeks to three months
Only one trial reported HRQoL, using the SF-36 scale (Varadaraju-
lu 2013). Data for general health perception were obtained to com-
pare the HRQoL results (range of scores: 0 to 100, with 100 indicat-
ing maximum health). Health-related quality of life was statistical-
ly significantly worse in the open surgical drainage group than in
the EUS-guided drainage group, using the RevMan statistical algo-
rithm (MD -21.00; 95% CI -33.21 to -8.79; participants = 40; studies =
1; Analysis 1.3). Since this was the only trial reporting the outcome,
a network meta-analysis was not performed and the issues of fixed-
effect model versus random-effects model and heterogeneity did
not arise.
Medium term: three months to one year and long-term: more than one
year
None of the trials reported HRQoL at medium-term (three months
to one year) or long-term (more than one year).
Secondary outcomes
1. Adverse events
All four trials (176 participants) reported adverse events of any
severity (Park 2009; Varadarajulu 2008; Varadarajulu 2013; Yuan
2015).
Direct comparison
As shown in Analysis 1.4, the proportion of people with any ad-
verse events was statistically significantly lower with EUS-guid-
ed drainage with nasocystic drainage compared to EUS-guided
drainage (OR 0.20; 95% CI 0.06 to 0.73; participants = 47; studies =
1). There were no statistically significant differences in any of the
remaining direct comparisons (endoscopic drainage versus EUS-
guided drainage: OR 2.42; 95% CI 0.51 to 11.46; participants = 89;
studies = 2; open surgical drainage versus EUS-guided drainage: OR
11.18; 95% CI 0.56 to 222.98; participants = 40; studies = 1). There
was no evidence of heterogeneity in the comparison of endoscop-
ic drainage versus EUS-guided drainage (I2 = 0; Chi2 test for hetero-
geneity = 0.53; Tau2 statistic = 0; or visual inspection). There was no
difference in the interpretation of results using fixed-effect or ran-
dom-effects models.
The absolute unadjusted proportions of people with adverse
events in different interventions are:
1. EUS-guided drainage 17.0% (15/88);
2. Endoscopic drainage 11.4% (5/44);
3. EUS-guided drainage with nasocystic drainage 20.8% (5/24);
4. Open surgical drainage 20.0% (4/20).
Indirect comparison
As shown in Figure 4, those who received EUS-guided drainage with
nasocystic drainage had fewer adverse events when compared to
endoscopic drainage (OR 0.08; 95% CI 0.01 to 0.61) or open drainage
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(OR 0.02; 95% CI 0.00 to 0.46). There was no statistically signifi-
cant differences in the proportion of people with adverse events
between the endoscopic drainage and open drainage groups (OR
0.22; 95% CI 0.01 to 6.32).
2. Measures of decreased complications and earlier recovery
(within three months)
2a. Length of hospital stay
Three trials (116 participants) reported length of hospital stay
(Varadarajulu 2008; Varadarajulu 2013; Yuan 2015).
Direct comparison
As shown in Analysis 1.5, the length of hospital stay was statistical-
ly significantly shorter in the EUS-guided drainage with nasocystic
drainage compared to EUS-guided drainage (MD -8.10 days; 95% CI
-9.79 to -6.41; participants = 47; studies = 1), and statistically signif-
icantly longer in the open surgical drainage group compared to the
EUS-guided drainage group (MD 4.20 days; 95% CI 2.82 to 5.58; par-
ticipants = 40; studies = 1). There was no statistically significant dif-
ference in the comparison between endoscopic drainage and EUS-
guided drainage (MD -1.00 days; 95% CI -2.53 to 0.53; participants
= 29; studies = 1). Since there was only one study for the different
comparisons, the issues of heterogeneity and fixed-effect versus
random-effects model did not arise. Exclusion of one trial in which
the mean was imputed from the median, and the standard devia-
tion was calculated from the P value did not alter the interpreta-
tion of results, other than there was no information available in the
comparison of hospital stays between the endoscopic drainage and
EUS-guided drainage groups (Varadarajulu 2008).
Indirect comparison
As shown in Figure 4, the EUS-guided drainage with nasocystic
drainage group had a shorter hospital stay compared to the endo-
scopic drainage group (MD -7.10 days; 95% CI -9.38 to -4.82), or open
surgical drainage group (MD -12.30 days; 95% CI -14.48 to -10.12).
The endoscopic drainage group had a shorter hospital stay than the
open drainage group (MD -5.20 days; 95% CI -7.26 to -3.14).
2b & 2c.Time-to-return to normal activity and time-to-return to
work
None of the trials reported either the time-to-return to normal ac-
tivity or the time-to-return to work.
3. Need for additional invasive intervention
Three trials (129 participants) reported that additional invasive in-
terventions were required for drainage (Park 2009; Varadarajulu
2008; Varadarajulu 2013).
Direct comparison
As shown in Analysis 1.6, the proportion of people requiring ad-
ditional invasive intervention for drainage was statistically signifi-
cantly higher with endoscopic drainage than EUS-guided drainage
(OR 11.13; 95% CI 2.85 to 43.44; participants = 89; studies = 2). There
was moderate heterogeneity (I2 = 44%; Chi2 test for heterogeneity
= 0.18; Tau2 statistic = 1.21; and visual inspection), but the hetero-
geneity appeared to be in the magnitude rather than direction of
effect. There was no difference in the interpretation of results us-
ing either fixed-effect or random-effects models for this compari-
son. There were no statistically significant differences in the need
for additional drainage between the open surgical and EUS-guid-
ed drainage groups (OR 0.47; 95% CI 0.04 to 5.69; participants = 40;
studies = 1).
The absolute unadjusted proportions of need for additional
drainage in different interventions were:
1. EUS-guided drainage 6.2% (4/65);
2. Endoscopic drainage 40.9% (18/44);
3. Open surgical drainage 5.0% (1/20).
Indirect comparison
As shown in Figure 4, the proportion of people requiring addition-
al drainage was statistically significantly more in the endoscopic
drainage group than in the open surgical drainage group (OR 23.69;
95% CI 1.40 to 400.71).
4. Costs
Only one trial reported costs (Varadarajulu 2013). Treatment costs
were statistically significantly higher in the open surgical drainage
group compared to the EUS-guided drainage group, using the
RevMan statistical algorithm (MD 8040 USD; 95% CI 3020 to 13,060;
participants = 40; studies = 1; Analysis 1.7). Since this was the only
trial reporting the outcome, we did not perform a network meta-
analysis, and the issues of fixed-effect versus random-effects mod-
el and heterogeneity did not arise.
Subgroup analysis
We did not perform any of the planned subgroup analyses. Three
trials included only symptomatic patients with pseudocysts (Park
2009; Varadarajulu 2008; Varadarajulu 2013). This information was
not available in Yuan 2015. Two studies included patients with
a pseudocyst from acute or chronic pancreatitis due to various
aetiologies, but did not report the data separately (Park 2009;
Varadarajulu 2013). The remaining two trials did not report whether
the pseudocyst was associated with acute or chronic pancreatitis.
None of the trials provided separate data for pseudocysts of differ-
ent sizes.
Sensitivity analyses
We did not perform the sensitivity analysis of excluding trials at un-
clear or high risk of bias, since all the trials fell into this category. We
did not perform a sensitivity analysis of imputation of binary out-
comes under 'best-best', 'best-worst', 'worst-best', or 'worst-worst'
scenarios because we did not consider that the exclusion of one
patient due to pancreatic adenoma would result in attrition bias
(please see 'Incomplete outcome data (attrition bias)'). The sensi-
tivity analysis of excluding trials in which the mean, standard devi-
ation, or both were imputed has been presented under the individ-
ual outcomes.
Reporting bias
We did not explore reporting bias using a funnel plot because we
had fewer than 10 trials for each comparison.
D I S C U S S I O N
Summary of main results
We included four randomised controlled trials that included 176
participants and compared different methods of draining pseudo-
cysts with EUS-guided drainage (Park 2009; Varadarajulu 2008;
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Varadarajulu 2013; Yuan 2015). Network meta-analysis provided in-
ferior quality of evidence than direct comparison for all compar-
isons that used EUS-guided drainage as the control group because
of the indirectness it introduces, particularly since we were unable
to assess the transitivity assumption. However, it provided the ef-
fect estimates for other pair-wise comparisons when direct com-
parison was not available, the reliability of such effect estimates
when the transitivity assumption could not be tested formally is not
known.
There were no statistically significant differences between the
treatments in short-term mortality or the proportion of people with
serious adverse events. Short-term (four weeks to three months)
health-related quality of life (HRQoL) was worse and the costs were
higher in the open surgical drainage group than in the EUS-guid-
ed drainage group. Participants who received EUS-guided drainage
with nasocystic drainage had fewer adverse events when compared
to those who received either EUS-guided or endoscopic drainage.
Participants who received EUS-guided with nasocystic drainage
also had shorter hospital stays when compared to EUS-guided
drainage, endoscopic drainage, or open surgical drainage, while
those who received open surgical drainage had longer hospital
stays than those who received EUS-guided drainage. The need for
additional invasive interventions was significantly higher with en-
doscopic drainage than with EUS-guided drainage, while it was sta-
tistically significantly lower in those who received open surgical
drainage than in those who received endoscopic drainage. There
were no statistically significant differences in the other compar-
isons.
None of the trials reported on long-term mortality, medium-term
HRQoL (three months to one year), long-term HRQoL (longer than
one year), time-to-return to normal activities, or time-to-return to
work.
Overall completeness and applicability of evidence
Three trials only included symptomatic patients with pseudocysts
(Park 2009; Varadarajulu 2008; Varadarajulu 2013), while Yuan 2015
did not state whether asymptomatic patients were included. So,
the results of this study are only applicable for symptomatic pa-
tients with pseudocysts. Two trials clearly stated that they included
pseudocysts that had resulted from acute or chronic pancreatitis
due to various aetiologies (Park 2009; Varadarajulu 2013). The re-
maining two trials did not report on this association. Nevertheless,
it appears that the results are applicable to patients with pseudo-
cysts resulting from acute and chronic pancreatitis, the major caus-
es of pseudocysts. The mean size of the pseudocysts ranged be-
tween 70 mm and 155 mm across all included studies. Thus, the
results of this review are applicable for moderate to large pseudo-
cysts. Infected pseudocysts were excluded in two trials (Park 2009;
Varadarajulu 2008). This information was not available in the re-
maining two trials (Varadarajulu 2013; Yuan 2015). So, the results of
this review are only applicable for non-infected pseudocysts.
Quality of the evidence
The overall quality of evidence was low or very low for all the out-
comes. There was no blinding of outcome assessors for any of the
comparisons. All statistically significant outcomes were subjective
outcomes and may be influenced by the lack of blinding. As a re-
sult, the risk of bias was unclear or high for most of the outcomes.
It was not possible to assess the consistency of evidence since two
comparisons, EUS-guided drainage with nasocystic drainage ver-
sus EUS-guided drainage and open surgical drainage versus EUS-
guided drainage had only one trial. There was no evidence of incon-
sistency in the comparison of endoscopic drainage with EUS-guid-
ed drainage for serious adverse and adverse events, while there was
moderate inconsistency for the need for additional drainage for the
same comparison. However, the inconsistency in the need for ad-
ditional drainage appears to be in the magnitude, rather than in the
direction of effect. We were unable to assess the consistency for
length of hospital stay since only one of the two trials comparing en-
doscopic drainage with EUS-guided drainage reported it (Varadara-
julu 2008). Another major issue was the small sample size in the tri-
als, which resulted in imprecise results.
Potential biases in the review process
We followed the guidance in the NICE DSU documents and the
Cochrane Handbook for Systematic Reviews of Interventions for the
direct comparisons in the review (Dias 2013; Higgins 2011). Two
people selected studies and extracted data, reducing the errors in
data collection. We used formal search strategies to identify trials.
While the likelihood of missing trials from identified references is
low, the search strategy included the time-frame before the manda-
tory trial registration era and it is possible that some trials were not
reported in journals because of their results. However, one has to
be pragmatic and accept that this is the best evidence that is cur-
rently available.
We imputed the mean and calculated the standard deviation for
length of hospital stay for one trial from the median and P value
(Varadarajulu 2008). Excluding this trial altered the conclusions by
withdrawing information on the length of hospital stay for those
who received endoscopic drainage.
While network meta-analysis has its advantages in combining di-
rect and indirect evidence (resulting in more precise evidence) and
Bayesian network meta-analysis allows the calculation of the prob-
ability of best treatments, these advantages were limited in this
review because of the sparse data. All comparisons had at least
one trial that had no events in one arm, disallowing direct and in-
direct evidence for a single comparison. So, we conducted direct
comparisons using the Frequentist methods and conducted indi-
rect comparisons using the methods described in Bucher 1997. The
effect estimates of indirect comparisons and network meta-analy-
sis assume that the transitivity assumption is met. While the partic-
ipants appeared to be similar across trials of various comparisons,
we were unable to verify this using statistical methods, since none
of the comparisons had direct and indirect evidence. So, we were
not able to verify the transitivity assumption statistically. This de-
creases the confidence in indirect estimates.
Agreements and disagreements with other studies or
reviews
This is the first systematic review of randomised controlled trials
on pancreatic pseudocysts. There has been one previous review
comparing open surgical drainage with endoscopic or EUS-guid-
ed drainage for pancreatic pseudocysts, but this review included
non-randomised studies (Zhao 2016). The review authors conclud-
ed that the endoscopic group (endoscopic drainage or EUS-guid-
ed drainage) was associated with a shorter length of hospital stay
and lower hospital costs compared to the surgical group. We do not
agree with this conclusion, since there is significant uncertainty in
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these statements due to the small sample size in the trials, and the
lack of replication of the findings in two or more studies. In addi-
tion, only one trial included the costs of stent removal. None of the
trials included the complications and length of hospital stay result-
ing from stent removal. Although stent removal can be considered
a relatively minor procedure compared to the treatments, it does
incur costs and may cause complications and longer hospital stays.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Very low-quality evidence suggested that the differences in mor-
tality and serious adverse events between treatments were impre-
cise. Low-quality evidence suggested that short-term health-relat-
ed quality of life (four weeks to three months) was worse and the
costs were higher in the open surgical drainage group than in the
EUS-guided drainage group. Low-quality or very low-quality ev-
idence suggested that the EUS-guided drainage with nasocystic
drainage group had fewer adverse events compared to the EUS-
guided drainage or endoscopic drainage groups, and shorter hospi-
tal stays compared to those who received EUS-guided drainage, en-
doscopic drainage, or open surgical drainage, while those who re-
ceived EUS-guided drainage had shorter hospital stays than those
with open surgical drainage. Low-quality evidence suggested that
the need for additional invasive intervention was higher with endo-
scopic drainage than EUS-guided drainage, while it was lower in the
open surgical drainage than in the endoscopic drainage group.
Implications for research
Further randomised controlled trials are needed in patients with
symptomatic pancreatic pseudocysts requiring treatment. The
most effective interventions in this review appear to be EUS-guid-
ed drainage with or without nasocystic drainage, so, it is reason-
able to start here. Other possible interventions include variations
of EUS-guided drainage (with or without nasocystic drainage) using
self-expanding stents (Huggett 2015), or EUS-guided drainage with
nasocystic drainage compared with laparoscopic drainage. Future
trials should include patient-oriented outcomes, such as mortality,
serious adverse events, health-related quality of life, length of hos-
pital stay, return-to-normal activity, and the number of work days
lost. All outcomes should be measured at least until the end of the
draining procedure and the removal of the stent, with a minimum
follow-up period of two to three years, to ensure there are no recur-
rences of pseudocysts.
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Characteristics of included studies [ordered by study ID]
 
Methods Randomised controlled trial
Participants Country: South Korea.
Number randomised: 60.
Post-randomisation drop-outs: not stated.
Revised sample size: 60.
Average age: 48 years.
Females: 13 (21.7%).
Symptomatic patients: 60 (100%).
Acute pancreatitis: 27 (45%).
Chronic pancreatitis: 28 (46.7%).
Infected pseudocyst: 0 (0%).
Mean size of pseudocyst in mm: 78
Follow-up time: minimum 6 months
Concomitant interventions: not stated
Inclusion criteria
1. History of pancreatitis.
2. Symptomatic pseudocysts with duration of longer than 4 weeks.
Exclusion criteria
1. Age less than 18 years.
2. A pancreatic pseudocyst more than 4 cm in size and communicating with the pancreatic duct.
3. A suggested pancreatic abscess or necrosis, shown by computed tomography (CT).
4. A moderate thickness (> 10 mm) from the cyst wall to the intramural wall, shown by EUS.
5. Portal hypertension or coagulopathy.
Interventions Participants were randomly assigned to two groups.
Group 1: Endoscopic EUS-guided drainage (N = 31).
Group 2: Endoscopic drainage (N = 29).
Outcomes The outcomes reported were short-term mortality, adverse events, and requirement for additional pro-
cedures.
Notes Source of funding: not stated.
Risk of bias
Park 2009 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "...randomly assigned by means of computer-generated numbers to
undergo….".
Allocation concealment
(selection bias)
Unclear risk Comment: This information was not available.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Quote: "... because this study was non-blinded, the inherent possibility of bias
may exist. However, blinding of an investigator to any technique to which pa-
tients are randomly assigned is impractical".
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Quote: "... because this study was non-blinded, the inherent possibility of bias
may exist. However, blinding of an investigator to any technique to which pa-
tients are randomly assigned is impractical".
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Comment: There were no post-randomisation drop-outs.
Selective reporting (re-
porting bias)
Low risk Comment: All important outcomes were reported.
Other bias Low risk Comment: No other source of bias.
Park 2009  (Continued)
 
 
Methods Randomised controlled trial
Participants Country: USA.
Number randomised: 30.
Post-randomisation drop-outs: 1 (3.3%).
Revised sample size: 29.
Average age: 47 years.
Females: 11 (37.9%).
Symptomatic patients: 29 (100%).
Acute pancreatitis: not stated
Chronic pancreatitis: not stated
Infected pseudocyst: 0 (0%).
Mean size of pseudocyst in mm: 70
Follow-up time: minimum 6 weeks
Concomitant interventions: not stated
Inclusion criteria
1. History of pancreatitis.
2. Symptomatic pseudocysts.
Exclusion criteria
1. CT findings were suggestive of pathology other than a pseudocyst.
2. Pseudocyst was ≤ 4 cm in size.
3. Patients younger than 18 years of age.
4. Patients with pancreatic abscess or necrosis by CT.
Interventions Participants were randomly assigned to two groups.
Group 1: Endoscopic EUS-guided drainage (N = 14).
Varadarajulu 2008 
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Group 2: Endoscopic drainage (N = 15).
Outcomes The outcomes reported were short-term mortality, adverse events, length of hospital stay, and require-
ment for additional procedures.
Notes Reasons for post-randomisation drop-outs: had septae on EUS and so the diagnosis was revised to pan-
creatic adenoma rather than pseudocyst, and patient underwent surgery.
Source of funding: not stated.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "After ERCP, an endoscopy nurse opened a sealed envelope that con-
tained computer-generated randomization assignments".
Allocation concealment
(selection bias)
Low risk Quote: "After ERCP, an endoscopy nurse opened a sealed envelope that con-
tained computer-generated randomization assignments".
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Quote: "Furthermore, the blinding of an investigator to the technique to which
the patient was randomized is neither feasible nor practical, and therefore, it
is difficult to exclude the possibility of bias completely".
Comment: It is impossible to blind the healthcare providers.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: This information was not available.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Comment: There was one post-randomisation drop-out in the EUS-guided
drainage group since septae were noted and the diagnosis was revised to pan-
creatic adenoma. This is an inherent advantage of EUS-guided drainage and
exclusion of the patient may have underestimated the overall benefit of EUS-
guided drainage. However, this is unlikely to influence any of the reported out-
comes.
Selective reporting (re-
porting bias)
Low risk Comment: All important outcomes were reported.
Other bias Low risk Comment: No other source of bias.
Varadarajulu 2008  (Continued)
 
 
Methods Randomised controlled trial
Participants Country: USA.
Number randomised: 40.
Post-randomisation drop-outs: not stated.
Revised sample size: 40.
Average age: 50 years.
Females: 12 (30%).
Symptomatic patients: 40 (100%).
Acute pancreatitis: 13 (32.5%).
Chronic pancreatitis: 27 (67.5%).
Infected pseudocyst: not stated
Mean size of pseudocyst in mm: 108
Follow-up time: minimum 24 months
Varadarajulu 2013 
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Concomitant interventions: not stated
Inclusion criteria
1. Diagnosis of pancreatic pseudocyst based on CT criteria.
2. Pseudocyst measuring ≥ 6 cm in size and located adjacent to the stomach.
3. Documented history of acute or chronic pancreatitis.
4. Persistent pancreatic pain requiring narcotics or analgesics.
5. Symptomatic gastric outlet or bile duct obstruction induced by the pseudocyst.
Exclusion criteria
1. Age < 18 or > 80 years.
2. Contraindications to surgery: ASA class IV, severe portal hypertension.
3. Contraindication to endoscopic drainage: gastrectomy with Billroth II reconstruction, gastric bypass
surgery, prior surgery for pancreas-related complications.
4. Pregnancy.
5. Associated pancreatic necrosis on CT.
6. Pseudocyst not adjacent to the stomach.
7. Multiloculated pseudocyst or multiple pseudocysts.
Interventions Participants were randomly assigned to two groups.
Group 1: Endoscopic EUS-guided drainage (N = 20).
Group 2: Open surgical drainage (N = 20).
Outcomes The outcomes reported were short-term mortality, adverse events, length of hospital stay, and require-
ment for additional procedures.
Notes Authors provided information on source of funding and length of hospital stay.
Source of funding: no funding (author reply).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Computer-generated randomization assignments were provided by
the statistician using a block randomization method".
Allocation concealment
(selection bias)
Low risk Quote: "The randomization assignments were placed in sequentially num-
bered, sealed, opaque envelopes and were opened by one of the study investi-
gators to determine treatment allocation".
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Quote: "We conducted a single-center, open-label, randomized trial to com-
pare endoscopic and surgical drainage….".
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Quote: "We conducted a single-center, open-label, randomized trial to com-
pare endoscopic and surgical drainage….".
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Comment: There were no post-randomisation drop-outs.
Selective reporting (re-
porting bias)
Low risk Comment: All important outcomes were reported.
Other bias Low risk Comment: No other source of bias.
Varadarajulu 2013  (Continued)
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Methods Randomised controlled trial
Participants Country: China.
Number randomised: 47.
Post-randomisation drop-outs: not stated.
Revised sample size: 47.
Average age: 48 years.
Females: 18 (38.3%).
Symptomatic patients: not stated
Acute pancreatitis: not stated
Chronic pancreatitis: not stated
Infected pseudocyst: not stated
Mean size of pseudocyst in mm: 155
Follow-up time: minimum 24 months
Concomitant interventions: not stated
Inclusion criteria
1. Ages 16 to 70 years.
2. Clinical presentation with abdominal distension with or without upper gastrointestinal obstruction.
3. Radiological findings suggestive of a pancreatic pseudocyst > 10 cm.
Exclusion criteria
1. Cysts without adherence to the gastric wall.
2. Distance between pseudocyst and gastric wall > 1 cm.
3. Pseudocyst communication with the main pancreatic duct.
4. Pregnancy.
5. Pancreatic tumours.
6. Risk for anaesthesia and surgery.
7. Contraindications to magnetic resonance cholangiopancreatography and endoscopic retrograde
cholangiopancreatography.
8. Liver cirrhosis.
9. Previous history of abdominal surgery (e.g., gastrectomy).
10. Inability to give informed consent.
Interventions Participants were randomly assigned to two groups.
Group 1: Endoscopic EUS-guided drainage (N = 23).
Group 2: Endoscopic EUS-guided drainage with nasocystic drainage (N = 24).
Outcomes The outcomes reported were short-term mortality, recurrence, and length of hospital stay.
Notes Source of funding: not stated.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: This information was not available.
Allocation concealment
(selection bias)
Low risk Quote: "Patients were randomized using sealed envelopes to undergo sin-
gle-step or 2-step treatment".
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk This information was not available.
Yuan 2015 
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: This information was not available.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Comment: This information was not available.
Selective reporting (re-
porting bias)
High risk Comment: Morbidity was not reported adequately.
Other bias Low risk Comment: No other source of bias.
Yuan 2015  (Continued)
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Sauer 2010 Comment on an included study (Varadarajulu 2008)
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title A Prospective Randomized Controlled Trial Comparing Laparoscopic Versus Endoscopic Drainage
for Pseudocyst of the Pancreas
Methods Randomised controlled trial
Participants Country: India
Estimated enrolment:60
Inclusion criteria
Symptomatic patients with pseudocyst of size more than 6 cm, more than 6-8 weeks duration after
an attack of acute pancreatitis.
Exclusion criteria
• Patients with chronic pancreatitis associated pseudocyst.• Patients who have undergone any form of intervention previously• Patients with significant co-morbidities• Patients unfit for general anaesthesia• Bleeding disorders• Patients refusing consent• Patients having significant necrotic debris not considered fit for endoscopic drainage. The pres-
ence of necrotic debris will be assessed by ultrasound of the abdomen and if required magnetic
resonance imaging. The volume of the cyst and that of necrotic debris will be calculated and sig-
nificant debris will be defined as >30% of debris volume/volume• Presence of a pseudoaneurysm
Interventions Participants randomly assigned to two groups.
Group 1: Laparoscopic cystogastrostomy
NCT02041793 
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Group 2: Endoscopic cystogastrostomy
Outcomes Primary outcome
Resolution of pseudocyst.
Secondary outcomes
Adverse events (bleeding, sepsis, chest complications and other important events in the post pro-
cedure period requiring prolonged stay and/or repeat procedure)
Cost per patient.
Recurrence rate of pseudocyst.
Starting date August 2011
Contact information Pramod K Garg, MD (pgarg10@hotmail.com)
Notes  
NCT02041793  (Continued)
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Comparison 1.   Management strategies for pancreatic pseudocysts
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Short-term mortality 4   Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Endoscopic drainage versus EUS-
guided drainage
2 89 Odds Ratio (M-H, Fixed, 95% CI) 3.0 [0.11, 79.91]
1.2 EUS-guided drainage with naso-
cystic drainage versus EUS-guided
drainage
1 47 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Open surgical drainage versus
EUS-guided drainage
1 40 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Serious adverse events 3   Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Endoscopic drainage versus EUS-
guided drainage
2 89 Odds Ratio (M-H, Fixed, 95% CI) 2.42 [0.51, 11.46]
2.2 Open surgical drainage versus
EUS-guided drainage
1 40 Odds Ratio (M-H, Fixed, 95% CI) 8.2 [0.40, 169.90]
3 Health-related quality of life (4
weeks to 3 months)
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Open surgical drainage versus
EUS-guided drainage
1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Adverse events 4   Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
4.1 Endoscopic drainage versus EUS-
guided drainage
2 89 Odds Ratio (M-H, Fixed, 95% CI) 2.42 [0.51, 11.46]
4.2 EUS-guided drainage with naso-
cystic drainage versus EUS-guided
drainage
1 47 Odds Ratio (M-H, Fixed, 95% CI) 0.20 [0.06, 0.73]
4.3 Open surgical drainage versus
EUS-guided drainage
1 40 Odds Ratio (M-H, Fixed, 95% CI) 11.18 [0.56, 222.98]
5 Hospital stay 3   Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 Endoscopic drainage versus EUS-
guided drainage
1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 EUS-guided drainage with naso-
cystic drainage versus EUS-guided
drainage
1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Open surgical drainage versus
EUS-guided drainage
1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Need for additional drainage 3   Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Endoscopic drainage versus EUS-
guided drainage
2 89 Odds Ratio (M-H, Fixed, 95% CI) 11.13 [2.85, 43.44]
6.2 Open surgical drainage versus
EUS-guided drainage
1 40 Odds Ratio (M-H, Fixed, 95% CI) 0.47 [0.04, 5.69]
7 Costs 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 Open surgical drainage versus
EUS-guided drainage
1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 1.1.   Comparison 1 Management strategies for pancreatic pseudocysts, Outcome 1 Short-term mortality.
Study or subgroup Other treat-
ments
EUS-guid-
ed drainage
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.1.1 Endoscopic drainage versus EUS-guided drainage  
Park 2009 0/29 0/31   Not estimable
Varadarajulu 2008 1/15 0/14 100% 3[0.11,79.91]
Subtotal (95% CI) 44 45 100% 3[0.11,79.91]
Total events: 1 (Other treatments), 0 (EUS-guided drainage)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.66(P=0.51)  
   
1.1.2 EUS-guided drainage with nasocystic drainage versus EUS-guid-
ed drainage
 
Favours other treatment 1000.01 100.1 1 Favours EUS drainage
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Study or subgroup Other treat-
ments
EUS-guid-
ed drainage
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Yuan 2015 0/24 0/23   Not estimable
Subtotal (95% CI) 24 23 Not estimable
Total events: 0 (Other treatments), 0 (EUS-guided drainage)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.1.3 Open surgical drainage versus EUS-guided drainage  
Varadarajulu 2013 0/20 0/20   Not estimable
Subtotal (95% CI) 20 20 Not estimable
Total events: 0 (Other treatments), 0 (EUS-guided drainage)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Not applicable  
Favours other treatment 1000.01 100.1 1 Favours EUS drainage
 
 
Analysis 1.2.   Comparison 1 Management strategies for pancreatic pseudocysts, Outcome 2 Serious adverse events.
Study or subgroup Other treat-
ments
EUS-guid-
ed drainage
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.2.1 Endoscopic drainage versus EUS-guided drainage  
Park 2009 3/29 2/31 79.92% 1.67[0.26,10.81]
Varadarajulu 2008 2/15 0/14 20.08% 5.37[0.24,122.29]
Subtotal (95% CI) 44 45 100% 2.42[0.51,11.46]
Total events: 5 (Other treatments), 2 (EUS-guided drainage)  
Heterogeneity: Tau2=0; Chi2=0.4, df=1(P=0.53); I2=0%  
Test for overall effect: Z=1.11(P=0.27)  
   
1.2.2 Open surgical drainage versus EUS-guided drainage  
Varadarajulu 2013 3/20 0/20 100% 8.2[0.4,169.9]
Subtotal (95% CI) 20 20 100% 8.2[0.4,169.9]
Total events: 3 (Other treatments), 0 (EUS-guided drainage)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.36(P=0.17)  
Test for subgroup differences: Chi2=0.49, df=1 (P=0.48), I2=0%  
Favours other treatment 2000.005 100.1 1 Favours EUS drainage
 
 
Analysis 1.3.   Comparison 1 Management strategies for pancreatic
pseudocysts, Outcome 3 Health-related quality of life (4 weeks to 3 months).
Study or subgroup Open drainage EUS-guided drainage Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
1.3.1 Open surgical drainage versus EUS-guided drainage  
Varadarajulu 2013 20 50.4 (19.7) 20 71.4 (19.7) -21[-33.21,-8.79]
Favours EUS drainage 2010-20 -10 0 Favours open drainage
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Analysis 1.4.   Comparison 1 Management strategies for pancreatic pseudocysts, Outcome 4 Adverse events.
Study or subgroup Other treat-
ments
EUS-guid-
ed drainage
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.4.1 Endoscopic drainage versus EUS-guided drainage  
Park 2009 3/29 2/31 79.92% 1.67[0.26,10.81]
Varadarajulu 2008 2/15 0/14 20.08% 5.37[0.24,122.29]
Subtotal (95% CI) 44 45 100% 2.42[0.51,11.46]
Total events: 5 (Other treatments), 2 (EUS-guided drainage)  
Heterogeneity: Tau2=0; Chi2=0.4, df=1(P=0.53); I2=0%  
Test for overall effect: Z=1.11(P=0.27)  
   
1.4.2 EUS-guided drainage with nasocystic drainage versus EUS-guid-
ed drainage
 
Yuan 2015 5/24 13/23 100% 0.2[0.06,0.73]
Subtotal (95% CI) 24 23 100% 0.2[0.06,0.73]
Total events: 5 (Other treatments), 13 (EUS-guided drainage)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.44(P=0.01)  
   
1.4.3 Open surgical drainage versus EUS-guided drainage  
Varadarajulu 2013 4/20 0/20 100% 11.18[0.56,222.98]
Subtotal (95% CI) 20 20 100% 11.18[0.56,222.98]
Total events: 4 (Other treatments), 0 (EUS-guided drainage)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.58(P=0.11)  
Test for subgroup differences: Chi2=9.29, df=1 (P=0.01), I2=78.47%  
Favours other treatment 2000.005 100.1 1 Favours EUS drainage
 
 
Analysis 1.5.   Comparison 1 Management strategies for pancreatic pseudocysts, Outcome 5 Hospital stay.
Study or subgroup Other treatments EUS-guided drainage Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
1.5.1 Endoscopic drainage versus EUS-guided drainage  
Varadarajulu 2008 15 1 (2.1) 14 2 (2.1) -1[-2.53,0.53]
   
1.5.2 EUS-guided drainage with nasocystic drainage versus EUS-guided drainage  
Yuan 2015 24 7.2 (1.6) 23 15.3 (3.8) -8.1[-9.79,-6.41]
   
1.5.3 Open surgical drainage versus EUS-guided drainage  
Varadarajulu 2013 20 6.9 (2.6) 20 2.7 (1.8) 4.2[2.82,5.58]
Favours EUS drainage 105-10 -5 0 Favours other treatment
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Analysis 1.6.   Comparison 1 Management strategies for
pancreatic pseudocysts, Outcome 6 Need for additional drainage.
Study or subgroup Other treat-
ments
EUS-guid-
ed drainage
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.6.1 Endoscopic drainage versus EUS-guided drainage  
Park 2009 8/29 2/31 88.75% 5.52[1.06,28.71]
Varadarajulu 2008 10/15 0/14 11.25% 55.36[2.75,1114.26]
Subtotal (95% CI) 44 45 100% 11.13[2.85,43.44]
Total events: 18 (Other treatments), 2 (EUS-guided drainage)  
Heterogeneity: Tau2=0; Chi2=1.79, df=1(P=0.18); I2=44.17%  
Test for overall effect: Z=3.47(P=0)  
   
1.6.2 Open surgical drainage versus EUS-guided drainage  
Varadarajulu 2013 1/20 2/20 100% 0.47[0.04,5.69]
Subtotal (95% CI) 20 20 100% 0.47[0.04,5.69]
Total events: 1 (Other treatments), 2 (EUS-guided drainage)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.59(P=0.56)  
Test for subgroup differences: Chi2=4.77, df=1 (P=0.03), I2=79.02%  
Favours other treatment 10000.001 100.1 1 Favours EUS drainage
 
 
Analysis 1.7.   Comparison 1 Management strategies for pancreatic pseudocysts, Outcome 7 Costs.
Study or subgroup Open drainage EUS-guided drainage Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
1.7.1 Open surgical drainage versus EUS-guided drainage  
Varadarajulu 2013 20 15.1 (10.7) 20 7 (4.2) 8.04[3.02,13.06]
Favours open drainage 105-10 -5 0 Favours EUS drainage
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Risk of biasStudy name
Inclusion and exclu-
sion criteria
Number of people in inter-
vention group
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Endoscopic drainage versus EUS guided drainage
Park 2009 31 29 Low Unclear High High Low Low Unclear
Inclusion criteria
1. History of pancreatitis.
2. Symptomatic pseudocysts with duration of longer than 4 weeks.
Exclusion criteria
1. Age less than 18 years.
2. A pancreatic pseudocyst more than 4 cm in size and communicating with the pancreatic duct.
3. A suggested pancreatic abscess or necrosis, shown by computed tomography (CT).
4. A moderate thickness (> 10 mm) from the cyst wall to the intramural wall, shown by EUS.
5. Portal hypertension or coagulopathy.
Varadarajulu 2008 14 15 Low Low High Unclear High Low Unclear
Inclusion criteria
1. History of pancreatitis.
2. Symptomatic pseudocysts.
Exclusion criteria
1. CT findings were suggestive of pathology other than a pseudocyst.
2. Pseudocyst was ≤ 4 cm in size.
3. Patients younger than 18 years of age.
4. Patients with pancreatic abscess or necrosis by CT.
EUS-guided drainage with nasocystic drainage versus EUS-guided drainage
Yuan 2015 23 24 Unclear Low Unclear Unclear Unclear High Unclear
Inclusion criteria
1. Ages 16 to 70 years.
2. Clinical presentation with abdominal distension with or without upper gastrointestinal obstruction.
3. Radiological findings suggestive of a pancreatic pseudocyst > 10 cm.
Exclusion criteria
1. Cysts without adherence to the gastric wall.
Table 1.   Characteristics table (arranged according to comparisons)  (Continued)
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2. Distance between pseudocyst and gastric wall greater than 1 cm.
3. Pseudocyst communication with the main pancreatic duct.
4. Pregnancy.
5. Pancreatic tumors.
6. Risk for anaesthesia and surgery.
7. Contraindications to magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography.
8. Liver cirrhosis.
9. Previous history of abdominal surgery (e.g. gastrectomy).
10. Inability to give informed consent.
Open surgical drainage versus EUS-guided drainage
Varadarajulu 2013 20 20 Low Low High High Low Low Low
Inclusion criteria
1. Diagnosis of pancreatic pseudocyst based on CT criteria.
2. Pseudocyst measuring >= 6 cm in size and located adjacent to the stomach.
3. Documented history of acute or chronic pancreatitis.
4. Persistent pancreatic pain requiring narcotics or analgesics.
5. Symptomatic gastric outlet or bile duct obstruction induced by the pseudocyst.
Exclusion criteria
1. Age < 18 or > 80 years.
2. Contraindications to surgery: ASA class IV, severe portal hypertension.
3. Contraindication to endoscopic drainage: gastrectomy with Billroth II reconstruction, gastric bypass surgery, prior surgery for pancreas-related complications.
4. Pregnancy.
5. Associated pancreatic necrosis on CT.
6. Pseudocyst not adjacent to the stomach.
7. Multiloculated pseudocyst or multiple pseudocysts.
Table 1.   Characteristics table (arranged according to comparisons)  (Continued)
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A P P E N D I C E S
Appendix 1. Glossary of terms
Acute: sudden.
Aetiology: cause.
Amylase: an enzyme that breaks down carbohydrates.
Aspiration cytology: inserting a hollow needle into the body to obtain cells from an organ and examining the cells under microscopy to
determine presence of cancer.
Cystoenterostomy: opening between the pseudocyst and small intestine.
Cystogastrostomy: opening between the pseudocyst and stomach.
Distal pancreatectomy: removal of body and tail of the pancreas.
Duodenal: relating to the first part of the small intestines.
Endoscopic: with the help of an endoscope, a tube inserted into the body (in this context, through the mouth and into the stomach and
upper part of the small intestine).
Enzyme: substances that enable and speed up chemical reactions that are necessary for the normal functioning of the body.
Epigastric pain: upper central abdominal pain.
Gastric: related to stomach.
Gastrointestinal tract: digestive tract.
Haemorrhage: bleeding.
Insulin: substance which helps regulate blood sugar.
Intrapancreatic: within the pancreas.
Morbidity: illness (in this context, it means complications)
Mortality: death
Necrosis: death and decomposition of living tissue, usually caused by lack of blood supply, but can be caused by other pathological insult.
Neoplasm: tumour.
Oesophagoduodenoscope: inserting an endoscope, a tube inserted into the food pipe and stomach to view them internally (in this con-
text).
Pathologic insult: substance or mechanism that causes the condition.
Percutaneous drainage: drainage carried out by insertion of a drain from the external surface of the body, usually guided by an ultrasound
or CT (computed tomography) scan.
Peripancreatic tissues: tissues surrounding the pancreas.
Peritoneal cavity: abdominal cavity (tummy).
Portal vein: vein that transports the blood from the intestines to the liver.
Pneumoperitoneum: inflation of the abdomen (tummy) with gas, in this context, because of a hole in the bowel.
Pseudoaneurysm: false aneurysm (blood clot outside the arterial wall formed by a leak through a hole in the artery; the leak is contained
by the surrounding tissues).
Protease: an enzyme that digests protein.
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Retroperitoneum: behind the abdominal cavity.
Serum: clear fluid that separates out when blood clots.
Sinistral portal hypertension: leK-sided portal hypertension (high pressure in the portal vein)
Splenic vein: vein that drains the spleen.
Stricture: narrowing of a passage within the body.
Thrombosis: blood clot.
Transenteric endoscopic management: drainage of the pseudocyst through the intestines.
Transient: temporary.
Transpapillary endoscopic management: drainage of the pseudocyst through the papilla (ampulla of Vater) which is formed by the union
of the pancreatic duct and the common bile duct.
Appendix 2. CENTRAL search strategy
#1 MeSH descriptor: [Pancreatic Pseudocyst] this term only
#2 (pancrea* near/2 pseudocyst*)
#3 MeSH descriptor: [Pancreatitis, Chronic] this term only and with qualifier(s): [Complications - CO]
#4 MeSH descriptor: [Constriction, Pathologic] this term only and with qualifier(s): [Complications - CO, Diagnosis - DI, Etiology - ET]
#5 MeSH descriptor: [Abscess] this term only
#6 pancrea*
#7 #5 and #6
#8 ((peri-pancreatic or peripancreatic or pancrea*) near/2 (abscess or fluid))
#9 #1 or #2 or #3 or #4 or #7 or #8
Appendix 3. MEDLINE search strategy
1. Pancreatic Pseudocyst/
2. (pancrea* adj2 pseudocyst*).mp.
3. Pancreatitis, Chronic/co [Complications]
4. Constriction, Pathologic/co, di, et [Complications, Diagnosis, Etiology]
5. Abscess/
6. pancrea*.mp.
7. 5 and 6
8. ((peri-pancreatic or peripancreatic or pancrea*) adj2 (abscess or fluid)).mp.
9. 1 or 2 or 3 or 4 or 7 or 8
10. randomized controlled trial.pt.
11. controlled clinical trial.pt.
12. randomized.ab.
13. placebo.ab.
14. drug therapy.fs.
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15. randomly.ab.
16. trial.ab.
17. groups.ab.
18. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
19. exp animals/ not humans.sh.
20. 18 not 19
21. 9 and 20
Appendix 4. EMBASE search strategy
1. Pancreatic Pseudocyst/
2. (pancrea* adj2 pseudocyst*).mp.
3. Pancreatitis, Chronic/co [Complications]
4. common bile duct obstruction/
5. common bile duct stenosis/
6. pancreas duct stenosis/
7. ((peri-pancreatic or peripancreatic or pancrea*) adj2 (abscess or fluid)).mp.
8. pancreas abscess/
9. pancreas juice/
10. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9
11. Clinical trial/
12. Randomized controlled trial/
13. Randomization/
14. Single-Blind Method/
15. Double-Blind Method/
16. Cross-Over Studies/
17. Random Allocation/
18. Placebo/
19. Randomi?ed controlled trial*.tw.
20. Rct.tw.
21. Random allocation.tw.
22. Randomly allocated.tw.
23. Allocated randomly.tw.
24. (allocated adj2 random).tw.
25. Single blind*.tw.
26. Double blind*.tw.
27. ((treble or triple) adj blind*).tw.
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28. Placebo*.tw.
29. Prospective study/
30. or/11-29
31. Case study/
32. Case report.tw.
33. Abstract report/ or letter/
34. or/31-33
35. 30 not 34
36. 10 and 35
Appendix 5. Science Citation Index search strategy
# 1 TS=((pancrea* near/2 pseudocyst*) OR ((peri-pancreatic or peripancreatic or pancrea*) near/2 (abscess or fluid)))
# 2 TS=(random* OR rct* OR crossover OR masked OR blind* OR placebo* OR meta-analysis OR systematic review* OR meta-analys*)
# 3 #2 AND #1
Appendix 6. ClinicalTrials.gov search strategy
"Interventional" [STUDY-TYPES] AND pseudocyst [DISEASE] AND ( "Phase 2" OR "Phase 3" OR "Phase 4" ) [PHASE]
Appendix 7. WHO ICTRP search strategy
pseudocyst
Appendix 8. Stata code for network plot
networkplot t1 t2, labels(T1 T2 T3 ...)
Appendix 9. Winbugs code
Source of code:
Consistency models: Dias 2014
Inconsistency models: White 2012 (modifications were performed for continuous, count, and time-to-event outcomes)
Binary outcome
Binary outcome - fixed-e0ect model
# Binomial likelihood, logit link
# Fixed effects model
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH STUDIES
mu[i] ˜ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
r[i,k] ˜ dbin(p[i,k],n[i,k]) # binomial likelihood
# model for linear predictor
logit(p[i,k]) <- mu[i] + d[t[i,k]] - d[t[i,1]]
# expected value of the numerators
rhat[i,k] <- p[i,k] * n[i,k]
#Deviance contribution
dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))
+ (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k])))
}
# summed residual deviance contribution for this trial
resdev[i] <- sum(dev[i,1:na[i]])
}
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totresdev <- sum(resdev[]) # Total Residual Deviance
d[1]<-0 # treatment effect is zero for reference treatment
# vague priors for treatment effects
for (k in 2:nt){ d[k] ˜ dnorm(0,.0001) }
# pairwise ORs and LORs for all possible pair-wise comparisons, if nt>2
for (c in 1:(nt-1)) {
for (k in (c+1):nt) {
or[c,k] <- exp(d[k] - d[c])
lor[c,k] <- (d[k]-d[c])
}
}
# ranking on relative scale
for (k in 1:nt) {
# rk[k] <- nt+1-rank(d[],k) # assumes events are “good”
rk[k] <- rank(d[],k) # assumes events are “bad”
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th best
}
} # *** PROGRAM ENDS
Binary outcome - random-e0ects model
# Binomial likelihood, logit link
# Random effects model
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH STUDIES
w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm
delta[i,1] <- 0 # treatment effect is zero for control arm
mu[i] ˜ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
r[i,k] ˜ dbin(p[i,k],n[i,k]) # binomial likelihood
logit(p[i,k]) <- mu[i] + delta[i,k] # model for linear predictor
rhat[i,k] <- p[i,k] * n[i,k] # expected value of the numerators
#Deviance contribution
dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))
+ (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k]))) }
# summed residual deviance contribution for this trial
resdev[i] <- sum(dev[i,1:na[i]])
for (k in 2:na[i]) { # LOOP THROUGH ARMS
# trial-specific LOR distributions
delta[i,k] ˜ dnorm(md[i,k],taud[i,k])
# mean of LOR distributions (with multi-arm trial correction)
md[i,k] <- d[t[i,k]] - d[t[i,1]] + sw[i,k]
# precision of LOR distributions (with multi-arm trial correction)
taud[i,k] <- tau *2*(k-1)/k
# adjustment for multi-arm RCTs
w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]])
# cumulative adjustment for multi-arm trials
sw[i,k] <- sum(w[i,1:k-1])/(k-1)
}
}
totresdev <- sum(resdev[]) # Total Residual Deviance
d[1]<-0 # treatment effect is zero for reference treatment
# vague priors for treatment effects
for (k in 2:nt){ d[k] ˜ dnorm(0,.0001) }
sd ˜ dunif(0,5) # vague prior for between-trial SD
tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance)
# pairwise ORs and LORs for all possible pair-wise comparisons, if nt>2
for (c in 1:(nt-1)) {
for (k in (c+1):nt) {
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or[c,k] <- exp(d[k] - d[c])
lor[c,k] <- (d[k]-d[c])
}
}
# ranking on relative scale
for (k in 1:nt) {
# rk[k] <- nt+1-rank(d[],k) # assumes events are “good”
rk[k] <- rank(d[],k) # assumes events are “bad”
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th best
}
} # *** PROGRAM ENDS
Binary outcome - inconsistency model (random-e0ects)
# Binomial likelihood, logit link, inconsistency model
# Random effects model
# Treatment by design interactions
# ns = number of studies, nt = number of treatments, A = total number of treatment arms in all trials, and D = the number of designs have
to be stated.
# The main data are arranged with one record per arm: d and study indicate which design and study that arm belongs to, t indicates its
treatment, and b indicates the first treatment in that design. r and n are the numbers of events and individuals in the arm. The supplemen-
tary data offset and offset.design list the rows in which the first arm of each trial and of each design is found.
model {
for(i in 1:ns) {
eff.study[i, b[offset[i]], b[offset[i]]] <-0
for(k in (offset[i] + 1):(offset[i + 1]-1)) {
eff.study[i,t[k],b[k]] <-eff.des[d[k],t[k]] + RE[i,t[k]] - RE[i,b[k]]
}
}
# Random effects for heterogeneity
for(i in 1:ns) {
RE[i,1] <-0
RE[i,2:nt] ˜ dmnorm(zero[], Prec[,])
}
# Prec is the inverse of the structured heterogeneity matrix
for(i in 1:(nt-1)) {
for(j in 1:(nt-1)){
Prec[i,j] <-2*(equals(i,j)-1/nt)/(tau*tau)
}
}
for(i in 1:A) {
logit(p[i]) <-mu[study[i]] + eff.study[study[i],t[i],b[i]]
r[i] ˜ dbin(p[i],n[i])}
# For computing DIC
for(i in 1:A) {
rhat[i] <-p[i] * n[i]
dev[i] <-2 * (r[i] * (log(r[i])-log(rhat[i])) + (n[i]-r[i]) * (log(n[i]-r[i]) - log(n[i]-
rhat[i])))
}
devs <-sum(dev[])
# Priors
for(i in 1:ns) {
mu[i] ˜ dnorm(0,0.01)
}
tau ˜ dunif(0,2)
} # *** PROGRAM ENDS
Continuous outcome (mean di>erence)
Continuous outcome (mean di0erence) - fixed-e0ect model
# Normal likelihood, identity link
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# Fixed effect model
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH STUDIES
mu[i] ˜ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
var[i,k] <- pow(se[i,k],2) # calculate variances
prec[i,k] <- 1/var[i,k] # set precisions
y[i,k] ˜ dnorm(theta[i,k],prec[i,k])
# model for linear predictor
theta[i,k] <- mu[i] + d[t[i,k]] - d[t[i,1]]
#Deviance contribution
dev[i,k] <- (y[i,k]-theta[i,k])*(y[i,k]-theta[i,k])*prec[i,k]
}
# summed residual deviance contribution for this trial
resdev[i] <- sum(dev[i,1:na[i]])
}
totresdev <- sum(resdev[]) #Total Residual Deviance
d[1]<-0 # treatment effect is zero for control arm
# vague priors for treatment effects
for (k in 2:nt){ d[k] ˜ dnorm(0,.0001) }
# ranking on relative scale
for (k in 1:nt) {
rk[k] <- rank(d[],k) # assumes lower is better
# rk[k] <- nt+1-rank(d[],k) # assumes lower outcome is worse
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th best
}
} # *** PROGRAM ENDS
Continuous outcome (mean di0erence) - random-e0ects model
# Normal likelihood, identity link
# Random effects model for multi-arm trials
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH STUDIES
w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm
delta[i,1] <- 0 # treatment effect is zero for control arm
mu[i] ˜ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
var[i,k] <- pow(se[i,k],2) # calculate variances
prec[i,k] <- 1/var[i,k] # set precisions
y[i,k] ˜ dnorm(theta[i,k],prec[i,k])
theta[i,k] <- mu[i] + delta[i,k] # model for linear predictor
#Deviance contribution
dev[i,k] <- (y[i,k]-theta[i,k])*(y[i,k]-theta[i,k])*prec[i,k]
}
# summed residual deviance contribution for this trial
resdev[i] <- sum(dev[i,1:na[i]])
for (k in 2:na[i]) { # LOOP THROUGH ARMS
# trial-specific MD distributions
delta[i,k] ˜ dnorm(md[i,k],taud[i,k])
# mean of MD distributions, with multi-arm trial correction
md[i,k] <- d[t[i,k]] - d[t[i,1]] + sw[i,k]
# precision of MD distributions (with multi-arm trial correction)
taud[i,k] <- tau *2*(k-1)/k
# adjustment, multi-arm RCTs
w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]])
# cumulative adjustment for multi-arm trials
sw[i,k] <- sum(w[i,1:k-1])/(k-1)
}
}
totresdev <- sum(resdev[]) #Total Residual Deviance
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d[1]<-0 # treatment effect is zero for control arm
# vague priors for treatment effects
for (k in 2:nt){ d[k] ˜ dnorm(0,.0001) }
sd ˜ dunif(0,5) # vague prior for between-trial SD
tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance)
# ranking on relative scale
for (k in 1:nt) {
rk[k] <- rank(d[],k) # assumes lower is better
# rk[k] <- nt+1-rank(d[],k) # assumes lower outcome is worse
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th best
}
} # *** PROGRAM ENDS
Continuous outcome (mean di0erence) - inconsistency model (random-e0ects)
# Normal likelihood, identity link, inconsistency model
# Random effects model
# Treatment by design interactions
# ns = number of studies, nt = number of treatments, A = total number of treatment arms in all trials, and D = the number of designs have
to be stated.
# The main data are arranged with one record per arm: d and study indicate which design and study that arm belongs to, t indicates its
treatment, and b indicates the first treatment in that design. y, se, and n are the mean, standard error, and number of individuals in the
arm. The supplementary data offset and offset.design list the rows in which the first arm of each trial and of each design is found.
model {
for(i in 1:ns) {
eff.study[i, b[offset[i]], b[offset[i]]] <-0
for(k in (offset[i] + 1):(offset[i + 1]-1)) {
eff.study[i,t[k],b[k]] <-eff.des[d[k],t[k]] + RE[i,t[k]] - RE[i,b[k]]
}
}
# Random effects for heterogeneity
for(i in 1:ns) {
RE[i,1] <-0
RE[i,2:nt] ˜ dmnorm(zero[], Prec[,])
}
# Prec is the inverse of the structured heterogeneity matrix
for(i in 1:(nt-1)) {
for(j in 1:(nt-1)){
Prec[i,j] <-2*(equals(i,j)-1/nt)/(tau*tau)
}
}
for(i in 1:A) {
var[i] <- pow(se[i],2) # calculate variances
prec[i] <- 1/var[i] # set precisions
y[i] ˜ dnorm(theta[i],prec[i]) # normal likelihood
theta[i] <-mu[study[i]] + eff.study[study[i],t[i],b[i]] # model for linear predictor
}
# For computing DIC
for(i in 1:A) {
dev[i] <- (y[i]-theta[i])*(y[i]-theta[i])*prec[i]
}
devs <-sum(dev[])
# Priors
for(i in 1:ns) {
mu[i] ˜ dnorm(0,0.01)
}
tau ˜ dunif(0,2)
for(i in 1:D) {
for(k in (offset.design[i] + 1):(offset.design[i] + num.ests[i])) {
eff.des[i,t[k]] ˜ dnorm(0,0.01)
}
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}
} # *** PROGRAM ENDS
Continuous outcome (standardised mean di>erence)
The standardised mean difference and its standard error for each treatment comparison will be calculated using the statistical algorithms
used by RevMan (RevMan 2014).
Continuous outcome (standardised mean di0erence) - fixed-e0ect model
# Normal likelihood, identity link
# Trial-level data given as treatment differences
# Fixed effects model
model{ # *** PROGRAM STARTS
for(i in 1:ns2) { # LOOP THROUGH 2-ARM STUDIES
y[i,2] ˜ dnorm(delta[i,2],prec[i,2]) # normal likelihood for 2-arm trials
#Deviance contribution for trial i
resdev[i] <- (y[i,2]-delta[i,2])*(y[i,2]-delta[i,2])*prec[i,2]
}
for(i in (ns2+1):(ns2+ns3)) { # LOOP THROUGH THREE-ARM STUDIES
for (k in 1:(na[i]-1)) { # set variance-covariance matrix
for (j in 1:(na[i]-1)) {
Sigma[i,j,k] <- V[i]*(1-equals(j,k)) + var[i,k+1]*equals(j,k)
}
}
Omega[i,1:(na[i]-1),1:(na[i]-1)] <- inverse(Sigma[i,,]) #Precision matrix
# multivariate normal likelihood for 3-arm trials
y[i,2:na[i]] ˜ dmnorm(delta[i,2:na[i]],Omega[i,1:(na[i]-1),1:(na[i]-1)])
#Deviance contribution for trial i
for (k in 1:(na[i]-1)){ # multiply vector & matrix
ydiff[i,k]<- y[i,(k+1)] - delta[i,(k+1)]
z[i,k]<- inprod2(Omega[i,k,1:(na[i]-1)], ydiff[i,1:(na[i]-1)])
}
resdev[i]<- inprod2(ydiff[i,1:(na[i]-1)], z[i,1:(na[i]-1)])
}
for(i in 1:(ns2+ns3)){ # LOOP THROUGH ALL STUDIES
for (k in 2:na[i]) { # LOOP THROUGH ARMS
var[i,k] <- pow(se[i,k],2) # calculate variances
prec[i,k] <- 1/var[i,k] # set precisions
delta[i,k] <- d[t[i,k]] - d[t[i,1]]
}
}
totresdev <- sum(resdev[]) #Total Residual Deviance
d[1]<-0 # treatment effect is zero for reference treatment
# vague priors for treatment effects
for (k in 2:nt){ d[k] ˜ dnorm(0,.0001) }
# ranking on relative scale
for (k in 1:nt) {
rk[k] <- nt+1-rank(d[],k) # assumes higher HRQoL is “good”
#rk[k] <- rank(d[],k) # assumes higher outcome is “bad”
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th best
}
} # *** PROGRAM ENDS
Continuous outcome (standardised mean di0erence) - random-e0ects model
# Normal likelihood, identity link
# Trial-level data given as treatment differences
# Random effects model
model{ # *** PROGRAM STARTS
for(i in 1:ns2) { # LOOP THROUGH 2-ARM STUDIES
y[i,2] ˜ dnorm(delta[i,2],prec[i,2]) # normal likelihood for 2-arm trials
#Deviance contribution for trial i
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resdev[i] <- (y[i,2]-delta[i,2])*(y[i,2]-delta[i,2])*prec[i,2]
}
for(i in (ns2+1):(ns2+ns3)) { # LOOP THROUGH THREE-ARM STUDIES
for (k in 1:(na[i]-1)) { # set variance-covariance matrix
for (j in 1:(na[i]-1)) {
Sigma[i,j,k] <- V[i]*(1-equals(j,k)) + var[i,k+1]*equals(j,k)
}
}
Omega[i,1:(na[i]-1),1:(na[i]-1)] <- inverse(Sigma[i,,]) #Precision matrix
# multivariate normal likelihood for 3-arm trials
y[i,2:na[i]] ˜ dmnorm(delta[i,2:na[i]],Omega[i,1:(na[i]-1),1:(na[i]-1)])
#Deviance contribution for trial i
for (k in 1:(na[i]-1)){ # multiply vector & matrix
ydiff[i,k]<- y[i,(k+1)] - delta[i,(k+1)]
z[i,k]<- inprod2(Omega[i,k,1:(na[i]-1)], ydiff[i,1:(na[i]-1)])
}
resdev[i]<- inprod2(ydiff[i,1:(na[i]-1)], z[i,1:(na[i]-1)])
}
for(i in 1:(ns2+ns3)){ # LOOP THROUGH ALL STUDIES
w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm
delta[i,1] <- 0 # treatment effect is zero for control arm
for (k in 2:na[i]) { # LOOP THROUGH ARMS
var[i,k] <- pow(se[i,k],2) # calculate variances
prec[i,k] <- 1/var[i,k] # set precisions
}
for (k in 2:na[i]) { # LOOP THROUGH ARMS
# trial-specific SMD distributions
delta[i,k] ˜ dnorm(md[i,k],taud[i,k])
# mean of random effects distributions, with multi-arm trial correction
md[i,k] <- d[t[i,k]] - d[t[i,1]] + sw[i,k]
# precision of random effects distributions (with multi-arm trial correction)
taud[i,k] <- tau *2*(k-1)/k
# adjustment, multi-arm RCTs
w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]])
# cumulative adjustment for multi-arm trials
sw[i,k] <- sum(w[i,1:k-1])/(k-1)
}
}
totresdev <- sum(resdev[]) #Total Residual Deviance
d[1]<-0 # treatment effect is zero for reference treatment
# vague priors for treatment effects
for (k in 2:nt){ d[k] ˜ dnorm(0,.0001) }
sd ˜ dunif(0,5) # vague prior for between-trial SD
tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance)
# ranking on relative scale
for (k in 1:nt) {
rk[k] <- nt+1-rank(d[],k) # assumes higher HRQoL is “good”
# rk[k] <- rank(d[],k) # assumes higher outcome is “bad”
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th best
}
} # *** PROGRAM ENDS
Continuous outcome (standardised mean di0erence) - inconsistency model (random-e0ects)
# Normal likelihood, identity link
# Trial-level data given as treatment differences
# Random effects model
model {
for(i in 1:ns) {
eff.study[i, t[i,1], t[i,1]] <-0
for(k in 2:na[i]) {
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eff.study[i,t[i,k],t[i,1]] <-eff.des[design[k],t[i,k]] + RE[i,t[i,k]] - RE[i, t[i,1]]
}
}
# Random effects for heterogeneity
for(i in 1:ns) {
RE[i,1] <-0
RE[i,2:nt] ˜ dmnorm(zero[], Prec[,])
}
# Prec is the inverse of the structured heterogeneity matrix
for(i in 1:(nt-1)) {
for(j in 1:(nt-1)){
Prec[i,j] <-2*(equals(i,j)-1/nt)/(tau*tau)
}
}
for(i in 1:ns2) { # LOOP THROUGH 2-ARM STUDIES
y[i,2] ˜ dnorm(delta[i,2],prec[i,2]) # normal likelihood for 2-arm trials
#Deviance contribution for trial i
resdev[i] <- (y[i,2]-delta[i,2])*(y[i,2]-delta[i,2])*prec[i,2]
}
for(i in (ns2+1):(ns2+ns3)) { # LOOP THROUGH THREE-ARM STUDIES
for (k in 1:(na[i]-1)) { # set variance-covariance matrix
for (j in 1:(na[i]-1)) {
Sigma[i,j,k] <- V[i]*(1-equals(j,k)) + var[i,k+1]*equals(j,k)
}
}
Omega[i,1:(na[i]-1),1:(na[i]-1)] <- inverse(Sigma[i,,]) #Precision matrix
# multivariate normal likelihood for 3-arm trials
y[i,2:na[i]] ˜ dmnorm(delta[i,2:na[i]],Omega[i,1:(na[i]-1),1:(na[i]-1)])
#Deviance contribution for trial i
for (k in 1:(na[i]-1)){ # multiply vector & matrix
ydiff[i,k]<- y[i,(k+1)] - delta[i,(k+1)] + eff.study[i,t[i,k],t[i,1]]
z[i,k]<- inprod2(Omega[i,k,1:(na[i]-1)], ydiff[i,1:(na[i]-1)])
}
resdev[i]<- inprod2(ydiff[i,1:(na[i]-1)], z[i,1:(na[i]-1)])
}
for(i in 1:(ns2+ns3)){ # LOOP THROUGH ALL STUDIES
w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm
delta[i,1] <- 0 # treatment effect is zero for control arm
for (k in 2:na[i]) { # LOOP THROUGH ARMS
var[i,k] <- pow(se[i,k],2) # calculate variances
prec[i,k] <- 1/var[i,k] # set precisions
}
for (k in 2:na[i]) { # LOOP THROUGH ARMS
# trial-specific SMD distributions
delta[i,k] ˜ dnorm(md[i,k],taud[i,k])
# mean of random effects distributions, with multi-arm trial correction
md[i,k] <- d[t[i,k]] - d[t[i,1]] + sw[i,k]
# precision of random effects distributions (with multi-arm trial correction)
taud[i,k] <- tau *2*(k-1)/k
# adjustment, multi-arm RCTs
w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]])
# cumulative adjustment for multi-arm trials
sw[i,k] <- sum(w[i,1:k-1])/(k-1)
}
}
totresdev <- sum(resdev[]) #Total Residual Deviance
d[1]<-0 # treatment effect is zero for reference treatment
# vague priors for treatment effects
for (k in 2:nt){ d[k] ˜ dnorm(0,.0001) }
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sd ˜ dunif(0,5) # vague prior for between-trial SD
tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance)
for(i in 1:D) {
for(k in (offset.design[i] + 1):(offset.design[i] + num.ests[i])) {
eff.des[i,t[i,k]] ˜ dnorm(0,0.01)
}
}
}
} # *** PROGRAM ENDS
Count outcome
Count outcome - fixed-e0ect model
# Poisson likelihood, log link
# Fixed effects model
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH STUDIES
mu[i] ˜ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
r[i,k] ˜ dpois(theta[i,k]) # Poisson likelihood
theta[i,k] <- lambda[i,k]*E[i,k] # failure rate * exposure
# model for linear predictor
log(lambda[i,k]) <- mu[i] + d[t[i,k]] - d[t[i,1]]
#Deviance contribution
dev[i,k] <- 2*((theta[i,k]-r[i,k]) + r[i,k]*log(r[i,k]/theta[i,k])) }
# summed residual deviance contribution for this trial
resdev[i] <- sum(dev[i,1:na[i]])
}
totresdev <- sum(resdev[]) #Total Residual Deviance
d[1]<-0 # treatment effect is zero reference treatment
# vague priors for treatment effects
for (k in 2:nt){ d[k] ˜ dnorm(0,.0001) }
# pairwise RRs and LRRs for all possible pair-wise comparisons, if nt>2
for (c in 1:(nt-1)) {
for (k in (c+1):nt) {
rater[c,k] <- exp(d[k] - d[c])
lrater[c,k] <- (d[k]-d[c])
}
}
# ranking on relative scale
for (k in 1:nt) {
# rk[k] <- nt+1-rank(d[],k) # assumes events are “good”
rk[k] <- rank(d[],k) # assumes events are “bad”
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th best
}
} # *** PROGRAM ENDS
Count outcome - random-e0ects model
# Poisson likelihood, log link
# Random effects model
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH STUDIES
w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm
delta[i,1] <- 0 # treatment effect is zero for control arm
mu[i] ˜ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
r[i,k] ˜ dpois(theta[i,k]) # Poisson likelihood
theta[i,k] <- lambda[i,k]*E[i,k] # failure rate * exposure
# model for linear predictor
log(lambda[i,k]) <- mu[i] + d[t[i,k]] - d[t[i,1]]
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#Deviance contribution
dev[i,k] <- 2*((theta[i,k]-r[i,k]) + r[i,k]*log(r[i,k]/theta[i,k])) }
# summed residual deviance contribution for this trial
resdev[i] <- sum(dev[i,1:na[i]])
for (k in 2:na[i]) { # LOOP THROUGH ARMS
# trial-specific LOR distributions
delta[i,k] ˜ dnorm(md[i,k],taud[i,k])
# mean of LOR distributions (with multi-arm trial correction)
md[i,k] <- d[t[i,k]] - d[t[i,1]] + sw[i,k]
# precision of LOR distributions (with multi-arm trial correction)
taud[i,k] <- tau *2*(k-1)/k
# adjustment for multi-arm RCTs
w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]])
# cumulative adjustment for multi-arm trials
sw[i,k] <- sum(w[i,1:k-1])/(k-1)
}
}
totresdev <- sum(resdev[]) # Total Residual Deviance
d[1]<-0 # treatment effect is zero for reference treatment
# vague priors for treatment effects
for (k in 2:nt){ d[k] ˜ dnorm(0,.0001) }
sd ˜ dunif(0,5) # vague prior for between-trial SD
tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance)
# pairwise ORs and LORs for all possible pair-wise comparisons, if nt>2
for (c in 1:(nt-1)) {
for (k in (c+1):nt) {
or[c,k] <- exp(d[k] - d[c])
lor[c,k] <- (d[k]-d[c])
}
}
# ranking on relative scale
for (k in 1:nt) {
# rk[k] <- nt+1-rank(d[],k) # assumes events are “good”
rk[k] <- rank(d[],k) # assumes events are “bad”
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th best
}
} # *** PROGRAM ENDS
Count outcome - inconsistency model (random-e0ects)
# Poisson likelihood, log link, inconsistency model
# Random effects model
# Treatment by design interactions
# ns = number of studies, nt = number of treatments, A = total number of treatment arms in all trials, and D = the number of designs have
to be stated.
# The main data are arranged with one record per arm: d and study indicate which design and study that arm belongs to, t indicates
its treatment, and b indicates the first treatment in that design. r and E are the numbers of successes and exposures in the arm. The
supplementary data offset and offset.design list the rows in which the first arm of each trial and of each design is found.
model {
for(i in 1:ns) {
eff.study[i, b[offset[i]], b[offset[i]]] <-0
for(k in (offset[i] + 1):(offset[i + 1]-1)) {
eff.study[i,t[k],b[k]] <-eff.des[d[k],t[k]] + RE[i,t[k]] - RE[i,b[k]]
}
}
# Random effects for heterogeneity
for(i in 1:ns) {
RE[i,1] <-0
RE[i,2:nt] ˜ dmnorm(zero[], Prec[,])
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}
# Prec is the inverse of the structured heterogeneity matrix
for(i in 1:(nt-1)) {
for(j in 1:(nt-1)){
Prec[i,j] <-2*(equals(i,j)-1/nt)/(tau*tau)
}
}
for(i in 1:A) {
r[i] ˜ dpois(theta[i]) # Poisson likelihood
theta[i] <- lambda[i]*E[i] # failure rate * exposure
log(lambda[i]) <-mu[study[i]] + eff.study[study[i],t[i],b[i]] # model for linear predictor
}
# For computing DIC
for(i in 1:A) {
dev[i] <- 2*((theta[i]-r[i]) + r[i]*log(r[i]/theta[i]))
}
devs <-sum(dev[])
# Priors
for(i in 1:ns) {
mu[i] ˜ dnorm(0,0.01)
}
tau ˜ dunif(0,2)
for(i in 1:D) {
for(k in (offset.design[i] + 1):(offset.design[i] + num.ests[i])) {
eff.des[i,t[k]] ˜ dnorm(0,0.01)
}
}
} # *** PROGRAM ENDS
Time-to-event outcome
Time-to-event outcome - fixed-e0ect model
# Binomial likelihood, cloglog link
# Fixed effects model
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH STUDIES
mu[i] ˜ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
r[i,k] ˜ dbin(p[i,k],n[i,k]) # Binomial likelihood
# model for linear predictor
cloglog(p[i,k]) <- log(time[i]) + mu[i] + d[t[i,k]] - d[t[i,1]]
rhat[i,k] <- p[i,k] * n[i,k] # expected value of the numerators
#Deviance contribution
dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))
+ (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k]))) }
# summed residual deviance contribution for this trial
resdev[i] <- sum(dev[i,1:na[i]])
}
totresdev <- sum(resdev[]) #Total Residual Deviance
d[1]<-0 # treatment effect is zero for control arm
# vague priors for treatment effects
for (k in 2:nt){ d[k] ˜ dnorm(0,.0001) }
# ranking on relative scale
for (k in 1:nt) {
# rk[k] <- rank(d[],k) # assumes lower is better
rk[k] <- nt+1-rank(d[],k) # assumes lower outcome is worse
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th best
}
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} # *** PROGRAM ENDS
Time-to-event outcome - random-e0ects model
# Binomial likelihood, cloglog link
# Random effects model
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH STUDIES
w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm
delta[i,1] <- 0 # treatment effect is zero for control arm
mu[i] ˜ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
r[i,k] ˜ dbin(p[i,k],n[i,k]) # Binomial likelihood
# model for linear predictor
cloglog(p[i,k]) <- log(time[i]) + mu[i] + delta[i,k]
rhat[i,k] <- p[i,k] * n[i,k] # expected value of the numerators
#Deviance contribution
dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))
+ (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k]))) }
# summed residual deviance contribution for this trial
resdev[i] <- sum(dev[i,1:na[i]])
for (k in 2:na[i]) { # LOOP THROUGH ARMS
# trial-specific LOR distributions
delta[i,k] ˜ dnorm(md[i,k],taud[i,k])
# mean of LOR distributions, with multi-arm trial correction
md[i,k] <- d[t[i,k]] - d[t[i,1]] + sw[i,k]
# precision of LOR distributions (with multi-arm trial correction)
taud[i,k] <- tau *2*(k-1)/k
# adjustment, multi-arm RCTs
w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]])
# cumulative adjustment for multi-arm trials
sw[i,k] <- sum(w[i,1:k-1])/(k-1)
}
}
totresdev <- sum(resdev[]) #Total Residual Deviance
d[1]<-0 # treatment effect is zero for reference treatment
# vague priors for treatment effects
for (k in 2:nt){ d[k] ˜ dnorm(0,.0001) }
sd ˜ dunif(0,5) # vague prior for between-trial SD
tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance)
# ranking on relative scale
for (k in 1:nt) {
# rk[k] <- rank(d[],k) # assumes lower is better
rk[k] <- nt+1-rank(d[],k) # assumes lower outcome is worse
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th best
}
} # *** PROGRAM ENDS
Time-to-event outcome - inconsistency model (random-e0ects)
# Binomial likelihood, cloglog link, inconsistency model
# Random effects model
# Treatment by design interactions
# ns = number of studies, nt = number of treatments, A = total number of treatment arms in all trials, and D = the number of designs have
to be stated.
# The main data are arranged with one record per arm: d and study indicate which design and study that arm belongs to, t indicates its
treatment, and b indicates the first treatment in that design. r ,n, and time are the numbers of events, individuals, and follow-up time in
the arm. The supplementary data offset and offset.design list the rows in which the first arm of each trial and of each design is found.
model {
for(i in 1:ns) {
eff.study[i, b[offset[i]], b[offset[i]]] <-0
for(k in (offset[i] + 1):(offset[i + 1]-1)) {
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eff.study[i,t[k],b[k]] <-eff.des[d[k],t[k]] + RE[i,t[k]] - RE[i,b[k]]
}
}
# Random effects for heterogeneity
for(i in 1:ns) {
RE[i,1] <-0
RE[i,2:nt] ˜ dmnorm(zero[], Prec[,])
}
# Prec is the inverse of the structured heterogeneity matrix
for(i in 1:(nt-1)) {
for(j in 1:(nt-1)){
Prec[i,j] <-2*(equals(i,j)-1/nt)/(tau*tau)
}
}
for(i in 1:A) {
r[i] ˜ dbin(p[i],n[i]) # Binomial likelihood
cloglog(p[i]) <- log(time[i]) + mu[study[i]] + eff.study[study[i],t[i],b[i]] # model for linear predictor
}
# For computing DIC
for(i in 1:A) {
dev[i] <- 2 * (r[i] * (log(r[i])-log(rhat[i]))+ (n[i]-r[i]) * (log(n[i]-r[i]) - log(n[i]-rhat[i])))
}
devs <-sum(dev[])
# Priors
for(i in 1:ns) {
mu[i] ˜ dnorm(0,0.01)
}
tau ˜ dunif(0,2)
for(i in 1:D) {
for(k in (offset.design[i] + 1):(offset.design[i] + num.ests[i])) {
eff.des[i,t[k]] ˜ dnorm(0,0.01)
}
}
} # *** PROGRAM ENDS
Appendix 10. Technical details of network meta-analysis
The posterior probabilities (effect estimates or values) of the treatment contrast (i.e., log odds ratio, mean difference, standardised mean
difference, rate ratio, or hazard ratio) may vary depending upon the initial values to start the simulations. In order to control the random
error due to the choice of initial values, we performed the network analysis for three different initial values (starting values) as per the
guidance from The National Institute for Health and Care Excellence (NICE) Decision Support Unit (DSU) documents (Dias 2013). If the
results from three different initial values were similar and stable (convergence), then the results are reliable. It is important to discard the
results of the initial simulations, as they can be significantly affected by the choice of the initial values, and only include the results of the
simulations obtained after the convergence. The discarding of the initial simulations is called 'burn in'. We had planned to run the models
for all outcomes for 30,000 simulations for 'burn in' for three different chains (a set of initial values). We had planned to run the models for
another 100,000 simulations to obtain the effect estimates. We had planned to obtain the effect estimates from the results of all the three
chains (different initial values). We had planned to ensure that the results in the three different chains were similar in order to control for
random error due to the choice of priors. We had planned to do this in addition to the visual inspection of convergence obtained after
simulations in the 'burn in'.
We had planned to run three different models for each outcome. A fixed-effect model assumes that the treatment effect is the same across
studies. The random-effects consistency model assumes that the treatment effect is distributed normally across the studies, but assumes
that the transitivity assumption is satisfied (i.e., the population studied, the definition of outcomes, and the methods used were similar
across studies and that there is consistency between the direct comparison and indirect comparison). A random-effects inconsistency
model does not make the transitivity assumption. If the inconsistency model resulted in a better model fit than the consistency model,
the results of the network meta-analysis could be unreliable and so should be interpreted with extreme caution. If there was evidence of
inconsistency, we had planned to identify areas in the network where substantial inconsistency might be present in terms of clinical and
methodological diversities between trials, and when appropriate, we had planned to limit network meta-analysis to a more compatible
subset of trials.
We had planned to base the choice of the model between fixed-effect and random-effects on the model fit as per the guidelines of the
NICE TSU (Dias 2013). The model fit was assessed by deviance residuals and Deviance Information Criteria (DIC) according to NICE TSU
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guidelines (Dias 2013). A difference of three or five in the DIC is not generally considered important (Dias 2012c). We had planned to use
the simpler model, i.e., the fixed-effect model, if the DIC were similar between the fixed-effect and the random-effects models. We had
planned to use the random-effects model if it resulted in a better model fit, as indicated by a DIC that was lower than the fixed-effect
model by at least three.
We had planned to calculate the effect estimates of the treatment and the 95% credible intervals using the following additional code:
# pairwise ORs and MD for all possible pairwise comparisons, if nt > 2
for (c in 1:(nt-1)) {
for (k in (c+1):nt) {
OR[c,k] <- exp(d[k] - d[c])
#MD[c,k] <- (d[k]-d[c])
}
}
where c indicates control group, k indicates intervention group, OR indicates odds ratio or other ratios, and MD indicates mean difference
or other differences.
Appendix 11. Winbugs code for subgroup analysis
Source of code: Dias 2012c
Categorical covariate
Only the code for random-effects model for a binary outcome is shown. The differences in the code are underlined. We had planned to
make similar changes for other outcomes.
# Binomial likelihood, logit link, subgroup
# Random effects model for multi-arm trials
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH STUDIES
w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm
delta[i,1] <- 0 # treatment effect is zero for control arm
mu[i] ˜ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
r[i,k] ˜ dbin(p[i,k],n[i,k]) # binomial likelihood
# model for linear predictor, covariate effect relative to treat in arm 1
logit(p[i,k]) <- mu[i] + delta[i,k] + (beta[t[i,k]]-beta[t[i,1]]) * x[i]
rhat[i,k] <- p[i,k] * n[i,k] # expected value of the numerators
#Deviance contribution
dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))
+ (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k]))) }
# summed residual deviance contribution for this trial
resdev[i] <- sum(dev[i,1:na[i]])
for (k in 2:na[i]) { # LOOP THROUGH ARMS
# trial-specific LOR distributions
delta[i,k] ˜ dnorm(md[i,k],taud[i,k])
# mean of LOR distributions (with multi-arm trial correction)
md[i,k] <- d[t[i,k]] - d[t[i,1]] + sw[i,k]
# precision of LOR distributions (with multi-arm trial correction)
taud[i,k] <- tau *2*(k-1)/k
# adjustment for multi-arm RCTs
w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]])
# cumulative adjustment for multi-arm trials
sw[i,k] <- sum(w[i,1:k-1])/(k-1)
}
}
totresdev <- sum(resdev[]) # Total Residual Deviance
d[1]<-0 # treatment effect is zero for reference treatment
beta[1] <- 0 # covariate effect is zero for reference treatment
for (k in 2:nt){ # LOOP THROUGH TREATMENTS
d[k] ˜ dnorm(0,.0001) # vague priors for treatment effects
beta[k] <- B[k] # exchangeable covariate effect
B[k] ˜ dnorm(0,.0001) # vague prior for covariate effect
}
Management strategies for pancreatic pseudocysts (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
54
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
sd ˜ dunif(0,5) # vague prior for between-trial SD
tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance)
# treatment effect when covariate = z[j]
for (k in 1:nt){ # LOOP THROUGH TREATMENTS
for (j in 1:nz) { dz[j,k] <- d[k] + (beta[k]-beta[1])*z[j] }
}
# *** PROGRAM ENDS
Continuous covariate
# Binomial likelihood, logit link, continuous covariate
# Random effects model for multi-arm trials
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH STUDIES
w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm
delta[i,1] <- 0 # treatment effect is zero for control arm
mu[i] ˜ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
r[i,k] ˜ dbin(p[i,k],n[i,k]) # binomial likelihood
# model for linear predictor, covariate effect relative to treat in arm 1
logit(p[i,k]) <- mu[i] + delta[i,k] + (beta[t[i,k]]-beta[t[i,1]]) * (x[i]-mx)
rhat[i,k] <- p[i,k] * n[i,k] # expected value of the numerators
#Deviance contribution
dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))
+ (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k]))) }
# summed residual deviance contribution for this trial
resdev[i] <- sum(dev[i,1:na[i]])
for (k in 2:na[i]) { # LOOP THROUGH ARMS
# trial-specific LOR distributions
delta[i,k] ˜ dnorm(md[i,k],taud[i,k])
# mean of LOR distributions (with multi-arm trial correction)
md[i,k] <- d[t[i,k]] - d[t[i,1]] + sw[i,k]
# precision of LOR distributions (with multi-arm trial correction)
taud[i,k] <- tau *2*(k-1)/k
# adjustment for multi-arm RCTs
w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]])
# cumulative adjustment for multi-arm trials
sw[i,k] <- sum(w[i,1:k-1])/(k-1)
}
}
totresdev <- sum(resdev[]) # Total Residual Deviance
d[1]<-0 # treatment effect is zero for reference treatment
beta[1] <- 0 # covariate effect is zero for reference treatment
for (k in 2:nt){ # LOOP THROUGH TREATMENTS
d[k] ˜ dnorm(0,.0001) # vague priors for treatment effects
beta[k] <- B[k] # exchangeable covariate effect
B[k] ˜ dnorm(0,.0001) # vague prior for covariate effect
}
sd ˜ dunif(0,5) # vague prior for between-trial SD
tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance)
# treatment effect when covariate = z[j] (un-centring treatment effects)
for (k in 1:nt){
for (j in 1:nz) { dz[j,k] <- d[k] - (beta[k]-beta[1])*(mx-z[j]) }
}
# pairwise ORs and LORs for all possible pair-wise comparisons, if nt>2
for (c in 1:(nt-1)) {
for (k in (c+1):nt) {
# at mean value of covariate
or[c,k] <- exp(d[k] - d[c])
lor[c,k] <- (d[k]-d[c])
# at covariate=z[j]
for (j in 1:nz) {
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orz[j,c,k] <- exp(dz[j,k] - dz[j,c])
lorz[j,c,k] <- (dz[j,k]-dz[j,c])
}
}
}
} # *** PROGRAM ENDS
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
1. We included endoscopic-guided drainage (EUS-guided drainage) with nasocystic drainage as an additional intervention. Generally, a
nasocystic catheter is used during EUS-guided drainage to irrigate the cyst, if there is a suspicion of presence of debris. The nasocystic
catheter is then generally removed, only retaining the stent between the stomach or duodenum and the pseudocyst. Yuan 2015 used
routine nasocystic drainage. This was considered to be a significant variation from standard EUS-guided drainage, so, it was included
as an intervention.
2. While network meta-analysis has its advantages in combining direct and indirect evidence (resulting in more precise evidence) and
Bayesian network meta-analysis allows the calculation of a probability of the best treatments, these advantages were limited in this
review because of the sparse data, with zero event trials and lack of direct and indirect evidence for any comparisons. So, we used Fre-
quentist methods, which allowed us to present information in the standard Cochrane format for direct comparisons; we also presented
indirect comparisons when able.
3. We had planned to use conservative treatment as the reference group. However, none of the trials included conservative treatment
as one of the arms. We plan to use EUS-guided drainage as the reference group in future updates, since this was the intervention that
was included in all the trials.
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Trials as Topic;  Ultrasonography, Interventional  [*methods]
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